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Vascular dysfunction commonly co-exists with kidney disease, which results 
in a substantially increased risk of cardiovascular disease (CVD). A severe, 
acute form of this vascular-renal phenotype is seen in those presenting with 
systemic vasculitis associated with autoantibodies to neutrophil cytoplasmic 
antigens (ANCA) - a rare inflammatory disorder. The most frequent severe 
manifestation of ANCA vasculitis involves endothelial injury giving rise to 
rapidly progressive glomerulonephritis in the kidney. Despite current 
treatments, overall survival remains poor with many patients suffering chronic 
inflammation, a major contributor to the development and progression of both 
CVD and chronic kidney disease (CKD). Indeed, those with CKD have a 
substantially higher chance of dying from CVD than of progressing to end-
stage renal disease (ESRD). Furthermore, those who respond to treatment 
remain at risk of further disease relapses. 
 
microRNAs (miRs) are selectively expressed in certain tissues and cell states, 
which makes them potential biomarker candidates. In the circulation, the miRs 
are bound to Argonaute 2 proteins or encapsulated in extracellular vesicles 
(ECVs). This makes them resistant to RNase degradation providing further 
support for their potential use as novel biomarkers. 
 
miR-126 is enriched in endothelial cells and is a regulator of vascular integrity 
and angiogenesis. miR-126 was measured in patients with active vasculitis 
and once in treatment-induced remission. At disease presentation, miR-126 
was at a low concentration and increased with successful treatment. Patients 
with vasculitis - both active disease and in remission states - had lower 
circulating miR-126 than in healthy volunteers. 
 
miR-126 was also measured in patients with ESRD to establish whether it was 
also a marker of chronic vascular dysfunction. Circulating levels were 
measured in patients receiving haemodialysis before and after the treatment. 
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Before haemodialysis, miR-126 was at a low level in circulating blood and 
increased after the treatment. The levels of miR-126 in patients with CKD were 
also measured and were at a higher concentration than patients with ESRD. 
These data suggest that miR-126 has a potential role as a biomarker of 
vascular health and could track the progression of vascular disease. 
 
Using small RNA sequencing, the miR profiles of patients with active vasculitis 
and once in remission were established. These results were analysed in order 
to determine appropriate miRs for biomarker discovery. Using the data 
obtained, the miR hits were measured in larger patient cohorts for validation. 
This did not result in the discovery of a specific miR biomarker for the 
identification of acute vascular dysfunction in humans. 
 
ECVs were isolated from healthy volunteers and patients with active vasculitis. 
Uptake of ECVs was established in human and mouse macrophages, as well 
as renal proximal tubules in vitro. This did not result in increased cytokine 
production in the cultured macrophages or renal cells. This suggests that 
uptake is possible, however, the ECV cargo does not activate immune and 
renal cells in vitro.  
 
These findings, therefore, show that circulating miRs are potential markers of 
acute and chronic human vascular dysfunction. miR-126 was a successful 
marker for differentiating between patients with active disease and treatment-
induced remission. The miR profile of these patients did not differ as 
determined by RNA sequencing. In addition, ECVs can be isolated from patient 
blood and taken up by recipient macrophage and renal proximal tubule cells, 
however, this does not result in a phenotypic change. These data suggest that 
miR-126 has a potential role as a biomarker of vascular health and could track 
the progression of vascular disease and response to treatment in acute and 




Blood vessel damage and kidney disease often occur in tandem, resulting in 
a greater chance of developing heart disease. ANCA vasculitis is a rare 
disease which causes blood vessel inflammation in any blood vessel in the 
body. If left untreated, the kidneys can be damaged and can progress to 
chronic kidney disease which may require dialysis due to reduced kidney 
function. Overall survival in ANCA vasculitis is low and the patient has a 
chance of relapsing. This means that better disease markers for diagnosis are 
required, as well as determining whether the treatment plans are working well 
for the patient and reducing the chance of disease relapse.  
 
The studies in this thesis aimed to define the role of small pieces of genetic 
material, known as microRNAs, as markers of the blood vessel damage. If this 
marker proves to be successful, it can be used as a diagnostic test in a clinical 
environment. The first study compared patients with ANCA vasculitis before 
and after they were treated for the condition and found that the level of 
microRNA-126 was substantially lower when they first presented with the 
disease, and this increased after treatment. Healthy volunteers had high levels 
of microRNA-126.These results were compared to currently used clinical tests, 
and there were evident correlations.  
 
The same microRNA was measured in patients with chronic kidney disease 
and patients on dialysis for end-stage renal disease. This showed that 
microRNA-126 is at a low level in chronic kidney disease patients and even 
lower in patients before their dialysis session. After dialysis, the amount of 
microRNA-126 increases, but not to the same level as healthy individuals. 
From this, it can be concluded that there is a lot of promise for microRNA-126 




To examine whether there were other microRNAs that could be used as 
biomarkers of ANCA vasculitis, patient samples were sequenced. This showed 
that multiple markers were different between active disease and remission. 
This suggests that the blood samples taken from patients have potential 
biomarkers of active disease in ANCA vasculitis.  
 
Finally, a study was carried out using the blood taken from patients with active 
ANCA vasculitis to discover whether the contents of the sample causes 
inflammation and damage in cells. This was carried out using immune cells 
that were produced from mice and healthy individuals, as well as kidney cells. 
The study demonstrated that there was minimal inflammation and damage in 
the cells tested and therefore the mechanism behind the vessel inflammation 






AAV ANCA associated vasculitis 
ADMA Asymmetric dimethylarginine 
Ago2 Argonaute 2 
ALP Alkaline phosphatase 
ALT Alanine transaminase 
ANCA Autoantibodies to neutrophil cytoplasmic antigens 
ANOVA Analysis of variance 
ARG1 Arginase 1 
AUC Area under the curve 
BAFF B-cell activating factor 
BLyS B lymphocyte stimulator 
BMDMΦ Bone marrow derived macrophages  
BVAS Birmingham vasculitis activity score 
CAD Coronary artery disease 
CKD Chronic kidney disease 
CRP C-reactive protein 
Ct Cycle threshold 




Diastolic blood pressure 
DILI Drug induced liver injury 
ECVs Extracellular vesicles 
eGFR Estimated glomerular filtration rate 
EGPA Eosinophilic granulomatosis with polyangiitis 
ENT Ear, nose and throat 
ESRD End-stage renal disease 
FBS Foetal bovine serum 
FLPM Full-length perfect match 
GAPDH Glyceraldehyde 3-phosphate dehydrogenase  
GFR Glomerular filtration rate 
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GGT Gamma-glutamyl transpeptidase 
GPA Granulomatosis with polyangiitis 
HD Haemodialysis 
IFG Impaired fasting glucose 
IGT Impaired glucose tolerance 
IL-10 Interleukin 10 
IL-1B Interleukin 1 Beta 
IL-6 Interleukin 6 
IRI Ischemic reperfusion injury 
KIM-1 Kidney injury molecule 1 
LAMP-2 Lysosome associated membrane protein 2 
LFTs Liver function tests 
MAP kinase Mitogen-activated protein kinase 
MCP-1 Monocyte chemoattractant protein 1 
MDRD Modification of Diet in Renal Disease  
miR microRNA 
MPA Microscopic polyangiitis 
MRC1 Mannose receptor 1 
mRNA Messenger RNA 
NETs Neutrophil extracellular traps 
NGS Next generation sequencing 
NIH National Institutes of Health 
NPM1 Nucleophosmin 1 
NTA Nanoparticle tracking analysis 
NTN Nephrotoxic nephritis 
PBMCs Peripheral blood mononuclear cells 
PBS Phosphate buffered saline 
PCA Principal component analysis 
PCR Polymerase chain reaction 
PD Peritoneal dialysis 
PFA Paraformaldehyde 
PI3KR2 Phosphoinositide-3-kinase regulatory subunit 2 
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PLG Plasminogen 
PWV Pulse wave velocity 
qRT-PCR Quantitative real time PCR 
RISC RNA-induced silencing complex 






Receiver operating characteristic 
Reactive oxygen species 





SPRED1 Sprouty-related, EVH1 domain-containing protein 1 
T2DM Type 2 diabetes mellitus 
TNFa Tumour necrosis factor alpha 
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The endothelium plays a fundamental role in vascular function through the 
regulation of vascular tone and maintenance of vascular homeostasis.1 The 
endothelium is a single layer of squamous endothelial cells that line the interior 
of all blood and lymphatic vessels in the body. It forms an interface between 
circulating blood or lymph in the lumen and for the rest of the vessel wall to 
control the flow of substances and fluid to the tissue. The molecular and 
functional properties of the endothelial cells will depend on the type of vessel 
or organ that they are present in. They are specialized depending on their 
microenvironment and signals including metabolic stimuli and growth factors, 
as well as cell matrix and cell-cell interactions.2 
 
Endothelial dysfunction is a systemic pathophysiological disorder. It is found 
in the presence of all traditional cardiovascular risk factors, including arterial 
hypertension, diabetes mellitus, obesity, and hypercholesterolaemia.3 In 
addition, it has been found to correlate with markers of low-grade chronic 
inflammation, such as C-reactive protein (CRP), which is a risk marker of 
cardiovascular diseases (CVD).4 Previous studies have reported that gold 
standard measures of renal function, including glomerular filtration rate (GFR), 
correlated with vascular dysfunction in patients with moderate renal 
impairment.5, 6 Vascular dysfunction is a key research focus for a range of 
CVDs, including kidney disease. 
 
ANCA vasculitis 
Vasculitis is the umbrella term used to describe aggressive rare inflammatory 
diseases of blood vessels. This encompasses small, medium and large 
vessels throughout the body. There are a multitude of causes of vasculitis and 
the clinical manifestations can be dependent on the site, type and size of 
vessels involved.7 Vasculitis can present with inflammation in any vessel from 
any organ system and this will influence the resulting disease characteristics. 
Patients can present with non-specific symptoms such as fever, malaise, and 
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weight loss. Progression of the disease depends on the specific vessels 
involved. Due to this, vasculitis is challenging to diagnose and has a high 
relapse and mortality rate. Vasculitis can potentially lead to life-threatening 
complications within days to weeks. Clinically, there is an unmet need for new 
diagnostic biomarkers to improve patient outcome by accelerating diagnosis 
and allowing for enhanced clinical guidance for treatment strategies.8 
 
Systemic vasculitis associated with autoantibodies to neutrophil cytoplasmic 
antigens (ANCA) are a group of systemic autoimmune diseases that affect 
small to medium-sized blood vessels throughout the body.9 Based on clinical 
diagnosis, ANCA associated vasculitis (AAV) is subcategorised into 
microscopic polyangiitis (MPA), granulomatosis with polyangiitis (Wegener’s, 
GPA), and eosinophilic granulomatosis with polyangiitis (Churg-Strauss, 
EGPA). In 90% of GPA and MPA cases, the patient’s ANCA status is 
positive.10 Differentiating between these conditions is challenging due to their 
clinical and pathological similarity which results in under-reporting of the 
disease. The annual incidence of the condition is estimated to occur in 
approximately 20-30 patients per million of population.11 However, this is 
thought to be an under-estimation due to an ageing population with more 
people reaching old-age than previous generations,12 as well as increased 
knowledge and awareness of the disease.13 Overall, the disease is 
characterised by necrosis and infiltration of leucocytes in the small arteries 
resulting in endothelial injury14. In severe cases, the inflammation can lead to 
glomerulonephritis in the kidney15 and haemorrhage in the lung.16 ANCA 
vasculitis is the most frequent cause of progressive glomerulonephritis 
globally.17 Even with current treatment strategies, the survival rate after the 
diagnosis of ANCA vasculitis is lower in comparison to unaffected cohorts with 
a 2.6 mortality ratio when compared to age and sex-matched counterparts.18, 
19 Patients suffer from chronic inflammation, which is a major contributor to the 
development of cardiovascular disease and chronic kidney disease.20 
Following successful treatment for the disease, the relapse rate remains at 
approximately 50% within 5 years.21   
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In the majority of ANCA vasculitis cases, patients present with renal 
involvement. In GPA, renal involvement occurs in 70% of cases. Almost 100% 
of MPA cases have renal involvement.22 Without successful 
immunosuppressive treatment, renal sclerotic lesions can develop which may 
progress to chronic kidney disease. The patient is often asymptomatic until 
advanced renal failure occurs.23 When ANCA vasculitis is localised in the 
kidney, this can result in glomerulonephritis. Early diagnosis of ANCA 
vasculitis and tracking response to treatment remains challenging. Currently 
used biomarkers of the disease are shown in Table 1. With renal involvement, 
serum creatinine is commonly utilised to measure renal function. However, this 
is inaccurate as the kidney is often severely damaged before the function is 
impaired to a measurable degree.24 Following treatment for the disease, 
creatinine may decrease yet it is not known whether inflammation continues 
after renal function improves. In those without renal involvement, there is not 
a reliable marker for disease activity. Measurement of circulating ANCA is 
useful for initial diagnosis25 but it is limited as a measure of disease activity 
over time. Currently, there are no biomarkers that are specific or reliable 
enough for small vessel inflammation.   The identification of such markers 
would not only allow early implementation of appropriate treatments but may 
also identify those patients with grumbling disease activity despite therapy, 
identify those who might safely stop long-term, potentially toxic, 
immunosuppression, and even predict disease relapses. 
 
ANCA negative patients are the minority of AAV patients, with clinicians being 
reluctant to give a definitive diagnosis without ANCA positivity.26 ANCA is a 
useful diagnostic biomarker in the correct clinical context and can be effective 
for patients with single organ involvement or atypical presentation. As a 
biomarker of disease activity, ANCA has been assessed by taking serial 
measurements in patients with AAV in order to predict disease relapse.  There 
have been conflicting opinions on whether this is an effective strategy.27  In a 
study of adult patients with GPA, a reduction in ANCA did not correlate with a 
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ANCA In clinical practice, it has a role as a diagnostic marker.29 ANCA is more useful in patients with 
renal involvement as persistent ANCA or rising titre is insufficient to change treatment plans. 
Pathogenic autoantibodies targeting antigens expression in neutrophil granules and surface.30  
B-cells Dysregulation leads to the activation of the inflammatory response and autoantibody 
production. They are non-specific and unable to differentiate infection from inflammation.31 
Haematuria/Proteinuria Demonstrates renal and glomerular damage or inflammation. This is a biomarker for renal 
involvement.32 
BAFF (BLyS) Inverse relationship with disease activity. It promotes B-cell differentiation and survival.33  




Autoantibodies that are directed towards a glycoprotein expressed in neutrophil granules and 
have potential as a diagnostic marker of AAV. Titres decrease rapidly after successful 
treatment and increase with relapse. The technique requires further development and 
standardisation.35  
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Anti-PLG autoantibodies Autoantibodies that are directed towards plasminogen and have a potential role as a diagnostic 
biomarker of AAV. This biomarker is observed in active disease and is yet to be examined for 
disease relapse. There are correlations with glomerular lesion severity.36, 37  
Anti-moesin autoantibodies This biomarker is at the research stage for AAV. Directed towards the heparin-binding protein 
moesin. There is no research currently on relapse.38 
ECVs Proposed role as a biomarker as they are involved in cell communication.39  
MCP-1 Circulating monocytes and tissue-resident macrophages are attracted to this chemokine. It is 
a biomarker for renal involvement. Higher levels are associated with disease relapse and a 
poor overall prognosis.40  
sCD163 Urinary biomarker - Higher in active disease with renal involvement when compared with 
remission.41 
sCD25 Urinary biomarker - The molecule is cleaved from activated T cells. When combined with 
sCD163, this can be used as a biomarker of renal involvement.42  
Table 1. Summary of currently used biomarkers of ANCA vasculitis. 




The role of inflammation in vascular disease 
The pathophysiology of vascular inflammation comprises an intricate 
interaction between immune cells, including neutrophils, monocytes and 
macrophages and endothelial cells, vascular smooth muscle cells and 
extracellular matrix. Vascular injury is linked with the recruitment of pro-
inflammatory cells by cytokines.44 These cytokines are fundamental for cell 
signalling and the promotion of systemic inflammation. Activated macrophages 
are tissue destructive in vessel wall inflammation and are the principal 
producers and up-regulators of inflammatory reactions. This is an essential 
part of vasculitis and the subsequent systemic inflammation.45 Macrophages 
are tissue-resident phagocytic cells and are fundamental for host defence. 
They process debris and foreign matter in all organs in the body. Macrophages 
are responsible for regulating the inflammatory response. Macrophage pattern 
recognition receptors enable them to interact with pathogens permitting them 
to recognise and phagocytose infected cells. In addition, macrophages are 
capable of secreting defence-relevant inflammatory mediators and 
cytokines.46 Macrophages bridge the innate and adaptive immune response, 
aided by their antigen-presenting capabilities.  
 
Macrophages play a major role in the pathogenesis of many CVDs.47 The 
mechanisms underpinning macrophage differentiation and activation in 
vascular inflammation have not been fully characterised. Macrophages 
pathology is determined by their functional phenotype. Depending on the 
environment, macrophages are capable of polarising into distinct functional 
subpopulations. Traditionally, these populations were simplified into a 
functional dichotomy of classically activated (M1) or alternatively activated 
(M2) macrophages. Classically activated macrophages produce a plethora of 
pro-inflammatory cytokines such as IL-1β, IL-6, IL-8, IL-12, IL-23, IL-27 and 
TNFα.48 These cytokines are considered to be tissue destructive.  In contrast, 
alternatively activated macrophages are fundamental for tissue repair and 
resolution of inflammation and are therefore considered to be anti-
inflammatory. They express cytokines such as IL-10, mannose receptor and 
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arginase 1 as well as exhibiting a protective effect by subduing immune cell 
recruitment49 and pro-inflammatory cytokine production.50 The overall 
macrophage phenotype is considered pivotal for determining their role in 
disease pathology. Recently, the traditional macrophage classification has 
evolved to describe the macrophage complexity more accurately. They are 
now defined based on established markers and activation stimuli which cause 
the differentiation.51 Patients with chronic inflammation are at an increased risk 
of cardiovascular morbidity and mortality. The link between vascular 
dysfunction and CVD has been well studied, however the mechanistic links 
between inflammatory diseases, endothelial dysfunction and CVD has not 
been fully understood. 
 
The mechanism of AAV 
The mechanism for ANCA causing AAV involves disproportionate ANCA-
mediated leucocyte activation which results in small vessel injury. When 
leucocytes are primed with inflammatory cytokines, including tumour necrosis 
factor (TNF-α) or microbial products in vitro, they express proteinase 3 (PR3) 
and myeloperoxidase (MPO) on their surface. PR3 and MPO-ANCA can 
subsequently activate primed monocytes and neutrophils. They bind to the 
antigens expressed on the surface of the cells or by Fc-receptor engagement52 
and this then initiates signal transduction cascades. Activated neutrophils 
degranulate, which causes a release of proteases and enzymes, including 
elastase, PR3 and MPO. There is also an increase in cell adhesions between 
neutrophils and endothelial cells, which is caused by ANCA inducing an 
increase of cell adhesion molecules. Chemotactic cytokines, including IL-1, 
MCP-1 and IL-8 are produced and released when ANCA binds to primed 
leucocytes. This then attracts more neutrophils and monocytes to the site of 
vessel inflammation. This directly impacts the chemotactic gradient, which 
under normal conditions would draw the neutrophils from the vasculature and 
into the tissue.  
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A further mechanism of AAV involves the formation of neutrophil extracellular 
traps (NETs). These are an essential component of the innate immune system, 
however, in excess, NET formation can damage small blood vessels. A vicious 
cycle is involved where ANCA stimulates NET production as well as NETs 
being involved in the production of ANCA.53 This is key to AAV pathogenesis 
(Figure 1). ANCA-activated neutrophils release factors that subsequently 
activate the alternative complement pathway, which produces C5a and 
increases the level of inflammation by attracting and priming more 
neutrophils.54 NETs have been identified in necrotising lesions associated with 
AAV. In contrast, they were not observed in ANCA-unrelated necrotising 
vasculitis. 
 
Figure 1. Mechanism of pathogenesis in AAV. 
Neutrophils and monocytes are stimulated by ANCA resulting in blood vessel inflammation and damage. 
 
AAV treatment 
The traditional and established treatment for AAV is high-dose 
cyclophosphamide and glucocorticoids. Studies have shown that this can 
achieve remission in approximately 75% of patients at 3 months and 90% at 6 
months.54 Unfortunately, relapse is common and there is a plethora of 
undesirable side effects which accompany AAV treatment. To limit these side 
effects, new therapies are being used at both the induction and maintenance 
phases, including biologic therapies (such as Rituximab), to reduce toxicity and 
improve effectiveness.55  
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Chronic kidney disease 
Chronic kidney disease (CKD) is the 16th leading cause of years of life lost 
worldwide.56 There is a well-defined association between CKD and CVD 
resulting in higher rates of morbidity and mortality. CKD is a critical 
independent risk factor for CVD.57  The risk of CVD increases with declining 
GFR and patients with CKD, that do not require dialysis, have a greater chance 
of dying from CVD than progressing to ESRD.57  
 
CKD typically evolves over many years, beginning with a prolonged period of 
silent disease.58 This makes disease diagnosis challenging and complicates 
any planning for the patient’s treatment options. Biomarkers of kidney function 
remain the gold standard for CKD assessment, with GFR being a fundamental 
clinical test.59 Estimated GFR (eGFR) is based on the Modification of Diet in 
Renal Disease study (MDRD) equation,60 which is 175 x (standardised serum 
creatinine)-1.154 x (age)-0.203 x 0.742 [if female] x 1.212 [if Black]. Early 
diagnosis is normally based on abnormal results for proteinuria and serum 
creatinine which leads to further investigation. Although this is clinically useful 
for identifying renal disease, these tests are limited and cannot allow for a 
specific diagnosis of the type of renal injury. A major issue with using serum 
creatinine for CKD diagnosis is that it is confounded by muscle mass and 
tubular secretion.61 This is also a challenge for tracking disease progression. 
A major issue is that there is a substantial loss of kidney function before 
creatinine concentration increases. In the context of acute kidney injury, 
creatinine also has sub-optimal sensitivity and specificity. Serum creatinine 
does not rapidly report a sudden change in renal function.24 
 
The stages of CKD are shown in Table 2.62 Stages 1 and 2 of CKD are 
considered to be mild with a GFR of 60 mL/min/1.73m2 or more. Moderate 
CKD is defined as a GFR of 15 to 59 mL/min/1.73m2. Once the patient’s GFR 




CKD stage Description GFR mL/min/1.73m2 
1 Renal damage with normal renal function ≥ 90 
2 Mildly decreased renal function 60 – 89 
3 Moderately decreased renal function 30 – 59  
4 Moderate to severely decreased renal function 15 – 29  
5 Renal failure (ESRD) <15 or haemodialysis 




Despite current treatment strategies, CKD progression to ESRD is still a major 
clinical and financial issue. Estimates suggest that there are currently over two 
million patients worldwide dependent on dialysis and this number continues to 
increase annually. By 2030, it has been predicted that this number will 
double.64, 65 The primary types of dialysis are haemodialysis (HD) and 
peritoneal dialysis (PD). In 2003, 67.5% of patients requiring renal replacement 
therapy received HD and 29.2% PD.66 Even with current treatment, patients 
on HD have high morbidity and mortality rates. In Europe, patients who 
commenced HD treatment between 2002 and 2006 had a survival rate of 
78.7% and 65.8% after 1 and 2 years, respectively.67, 68 Dialysis adequacy is 
measured clinically with the Kt/V index for a single treatment. For this 
measurement, K is the dialysis urea clearance, t is the total treatment time and 
V is the body volume that the urea is distributed.69 Kt/V has some limitations, 
especially for women and smaller patients in regard to the quantity of dialysis 
received. This can result in women receiving unnecessarily high dialysis 
dosing.70 ESRD require robust biomarkers to track disease progression and 
response to dialysis.   
 
Endothelial dysfunction has been suggested as a possible explanation for the 
increased CVD risk in CKD.71, 72 A longitudinal study of ESRD patients 
demonstrated that all-cause mortality was independently associated with 
endothelial dysfunction.73 There are limited data available for endothelial 
function in moderate and early stages of CKD, as most studies focus on ESRD. 
This would allow for interventions to prevent CVD deaths at earlier stages of 
CKD.  
 
Biomarkers of disease 
The National Institutes of Health (NIH) working group has defined a biomarker 
as “a characteristic that is objectively measured and evaluated as an indicator 
of normal biological processes, pathogenic processes, or pharmacological 
responses to therapeutic intervention”.74 Biomarkers are fundamental for the 
development of medical therapeutics and disease diagnostics. Due to the 
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complexity and diversity of biomarkers, there have been limitations in 
understanding chronic diseases. The FDA have developed a definition for the 
various categories of biomarker in order to optimise the concepts for research 
and medical advancements.75 Multiple definitions may apply to a single 
biomarker and validation and evidence must be available for each.  
 
Diagnostic biomarkers are intended for detection and confirmation of a 
disease, as well as identification of disease subtypes. This class of biomarker 
is expected to evolve with advancements in precision medicine. The main 
clinical significance of this class of biomarker is detecting the presence of a 
disease, as well as defining the classification or subtype of the disease. This 
requires a high level of precision, reliability and reproducibility, as well as being 
clinically affordable. It is essential to define the rate of false discovery in the 
patient population and ensure that it is not affected by the presence of 
confounding factors, such as comorbidities, age, smoking status and sex.76   
 
Monitoring biomarkers are used to measure the effect of a medical product, 
environmental factor, disease status or medical condition by performing serial 
measurements. They have a critical role in a clinical care setting. In 
cardiovascular disease, monitoring biomarkers are essential, including blood 
pressure and cholesterol control, for evaluation of the treatment strategy. A 
challenge with this category of biomarker is developing a comprehensive 
understanding of what the minor changes signal for the patient clinically and 
how it should influence their treatment.77 
 
Pharmacodynamic and response biomarkers change in response to exposure 
to a medical intervention or environmental factor. This category of biomarker 
is often used clinically and for the development of therapeutics. An example 
application for this type of biomarker is in clinical trials. Using 
pharmacodynamic and response biomarkers allow for the treatment success 
to be quantified. This can guide whether to continue developing a treatment.  
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Predictive biomarkers determine the positive or negative outcome for a patient 
following exposure to a medical product or environmental agent. Validation for 
this type of biomarker is challenging. Patients are ordinarily randomised into 
one or two treatment groups (or a placebo group) and the outcomes are 
compared for the presence, and level, of the biomarker. This demonstrates 
that a treatment is directly related to a clinical outcome and reflected in 
predictive biomarker.  
 
Prognostic biomarkers predict the probability of a clinical event, disease 
relapse or disease progression in patients with a defined disease or condition. 
This is considered a separate category to the susceptibility and risk category, 
which is more suitable for examining a healthy state to disease, rather than 
disease progression. Additionally, this class of biomarker is not affected by 
therapeutic intervention. They are often utilised in clinical trials to define entry 
and exclusion criteria in high-risk patient populations. This is essential for how 
statistical power is calculated based on the possibility of future events, as 
opposed to sample size. In a clinical care setting, it allows for evaluation of the 
possible length of treatment for a patient or their length of stay in hospital.  
 
Safety biomarkers are measured pre- or post-medical or environmental 
exposure to measure the probability or severity of toxicity. This is used as a 
measure of renal, hepatic and cardiovascular toxicity. This biomarker can be 
used for measuring the extent of an environmental exposure in the general 
population and clinically to assess the therapeutic toxicity in a patient 
population. A challenging aspect of this biomarker is defining the risk of toxicity 
of a treatment and the benefits for the patient receiving the treatment.  
 
Susceptibility and risk biomarkers establish whether an individual will possibly 
develop a disease who does not currently present with the condition. There 
are similarities for this classification with the prognostic biomarkers, however, 
there is a crucial difference in that this category relates to a disease or 
condition which the individual does not yet have. The main scope for 
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susceptibility and risk biomarkers are in examining the epidemiology of a 
disease.  
 
MicroRNAs as biomarkers 
The first microRNA (miR) identified was lin-4 in Caenorhabditis elegans in 
199378, 79 which subsequently led to the discovery of thousands of miRs and 
revolutionised molecular biology. miRs are a class of RNA molecules that are 
~22 nucleotide long, noncoding strands, which are involved in translational 
repression and cleavage.80 They play a role in post-transcriptional regulation 
of gene expression and RNA silencing. miRs are essential for the regulation 
of many protein-coding genes in a variety of organisms.81 They can exhibit 
organ specificity, which makes them a significant emerging class of biomarker 
for many diseases. As miRs are conserved in sequence across species they 
can be used in the pre-clinical setting as well as being translated for use in 
patients.82 Collectively, miRs play an important role in medicine, toxicology, 
pharmacology and cardiovascular disease. 
 
miR biogenesis begins with RNA polymerase II/III producing a primary 
transcript, known as a pri-miR. Pri-miRs contain a double-stranded hairpin loop 
with single-stranded sequences at both the 5’ and 3’ end. To ensure efficient 
processing, they must then be cleaved by Drosha, an RNase III superfamily 
enzyme.83 This forms a ~80 nucleotide precursor miR, known as a pre-miR. 
Following cleavage, they are exported from the nucleus to the cytoplasm by 
Exportin 5, a nucleocytoplasmic transporter. The pre-miR is further cleaved by 
Dicer to generate a miR duplex with two ~22 nucleotide mature miR strands. 
The mature miR can be bound to Argonaute 2 (Ago2) and incorporated into 
the RNA-induced silencing complex (RISC). It can then facilitate in post-
transcriptional regulation of mRNA.84  
 
Many miRs have conserved sequences between species, which allows for 
research carried out in animal models to be translated for human use. There 
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is an increasing volume of research suggesting that miRs are viable diagnostic 
or prognostic markers for diseases such as cancer and diabetes. In cancer, 
some miRs are even considered to be tumour suppressor genes.85 Numerous 
miRs have a tissue-specific expression profile, which indicates that they have 
the potential to be disease markers in the future. miRs are known to be 
expressed at elevated levels in some tissues and cell states, which make them 
an attractive biomarker candidate as the progress of the disease can be 
directly monitored. Samples can be taken which are minimally invasive to 
monitor circulatory miRs before and after therapeutic intervention. miRs can 
be found in tissue and in circulation. In the circulatory system, the strands are 
frequently attached to Ago2 proteins or encapsulated in extracellular vesicles 
(ECVs). This makes them somewhat resilient and resistant to RNase 




Figure 2. miR stability and transportation in the blood.  
To reduce RNase degradation, miRs are encapsulated in microparticles, exosomes, high- and low-
density lipoproteins. They are also attached to protein complexes, including Ago2.  
 
Extracellular vesicles 
Almost every cell type releases membrane-bound vesicles. ECVs were first 
described in 1967 and were observed in a diverse range of biological fluids. 
including blood, saliva and urine. They were considered to be systems for 
elimination of excess lipid and protein stores in the cell.87 In cell injury, the ECV 
cargo is altered which makes them a viable area for biomarker discovery, as a 
‘liquid biopsy’ as it is possible to differentiate between healthy and injured cells.  
 
ECVs can be categorised depending on their size and biogenesis. Exosomes 
are considerably smaller than other vesicles (20 – 100 nm in diameter) as well 
as differing in their chemical properties. Exosomes are released into the 
extracellular space and transfer cytoplasmic and membrane proteins as well 
as miRs and mRNA. They play an essential role in an array of cellular 
processes, such as mediating signalling between cells,88 making exosomes a 
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promising reservoir for biomarker discovery. Microvesicles are another unique 
class of ECV. They are released from the cell surface as a result of budding 
on the cell membrane. They are generally considered to be between 50 and 
1000nm in diameter. Their contents are similar to exosomes, including miRs, 
mRNA and proteins. Since there is cross-over in the size profile between 
exosomes and microvesicles, there is difficulty in characterising them 
definitively. For simplicity, both vesicle population will be referred to as ECVs 
(as per consensus statement guidance).89 Figure 3 shows the biogenesis of 




Figure 3. ECV biogenesis and the methods of uptake by recipient cells. 
Courtesy of Dr Emma Morrison. 
 
Sequencing technologies 
The most commonly used techniques for profiling miRs are sequencing, 
microarrays and qPCR. miRs have been identified in a variety of diseases 
using RNA sequencing (RNAseq). Due to their tissue-specific expression 
patterns, it is possible to compare the miRNome profile for multiple patient or 
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treatment cohorts in order to identify the unique signature for a disease. Using 
next-generation sequencing, tissue-specific miR expression patterns can be 
measured in targeted diseases. miRs have been discovered using this 
technique in many diseases, including cancer. One advantage of small 
RNAseq is that it allows for the discovery of novel miRs that were not 
detectable with traditional screening and profiling methods.90 Samples are 
prepared and sequenced to a known depth, allowing for a detailed analysis of 
the miR expression and subsequent hit validation to compare between active 
disease and remission.   
 
miR-126 
A miR of interest in cardiovascular disease is miR-126. It is located within the 
7th intron of the epidermal growth factor like domain 7 (EGFL7) gene, which 
resides on human chromosome 9. It is endothelial cell-enriched and present 
throughout the vasculature. miR-126 is fundamental for maintaining the 
vascular structure and to regulate many properties in endothelial cells, 
including cell migration, formation of the cytoskeleton, capillary network 
stability and cell mortality.91 It has been shown to positively regulate VEGF-
dependant PI3 kinase and MAP kinase signalling.92 This is done through 
directly targeting negative regulators of the VEGF signalling pathway (Figure 
4). miR-126 increases the proangiogenic actions of VEGF and FGF and 
stimulates blood vessel formation by repressing the expression of Spred-1, an 
intracellular inhibitor of angiogenic signalling. 
 
Studies in renal ischemic reperfusion injury (IRI) have demonstrated that miR-
126 has the potential to act as an angiomiR to modulate mobilisation of 
haemopoietic stem cells. This in turn promotes vascular integrity and renal 
recovery following IRI.93 In addition to renal injury, miR-126 has been shown 
to play a role in attenuating atherosclerosis.94 Studies have shown that 
atherosclerosis is attenuated by miR-126 delivery by apoptotic bodies.95  
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As a biomarker, miR-126 has been shown to have potential diagnostic and 
prognostic ability in type 2 diabetes mellitus (T2DM). For T2DM, studies have 
shown a relationship with circulating miR-126 and associations with pre-
diabetic syndrome.96 The study was conducted in a cohort of patient’s with 
impaired glucose tolerance (IGT), impaired fasting glucose (IFG), newly 
diagnosed T2DM patients and healthy individuals. The study found that miR-
126 was at a lower concentration in circulation in the T2DM patients than in 
the healthy controls. After six months of diet and exercise strategies, the 
concentration of miR-126 increased for the IGT and IFG groups. For patients 
with T2DM, a combination of diet and exercise with insulin increased the 
concentration of miR-126. This study suggested a role for miR-126 as a marker 
for pre-diabetes and T2DM, and the patient’s response to treatment. 
 
 
Figure 4. miR-126 regulates angiogenesis and vascular integrity.  
miR-126 positively regulates VEGF-dependant PI3 kinase and MAP kinase signalling. 
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In addition, miR-126 has been shown to be a potential biomarker for coronary 
artery disease (CAD). One study compared stable CAD patients with healthy 
volunteers and demonstrated that miR-126 was lower in the patient cohort.86 
This was also observed in a panel of other endothelial cell-enriched miRs 
(members of the miR-17 cluster). There was also differential expression for 
inflammatory marker miRs (e.g., miR-155). This study suggested that miR-126 
has potential as a biomarker of health and disease and the necessity to 
perform larger-scale studies to determine the use of circulating endothelial or 
vascular miRs in cardiovascular disease. 
 
A recent study examined the association between circulating miR-126 and 
CKD.97 In the study, over a 6-year period, 601 CKD patients (with stages G1 
to G5 and G5D) were compared with healthy controls to ascertain the 
differences in circulating miR-126 between groups. From CKD stage G2, miR-
126 levels were reduced in circulation with disease severity. In patients with a 
lower concentration of miR-126 than the median, a lower overall survival rate 
was observed in the follow-up period. In the study, miR-126 independently 
correlated with eGFR, haemoglobin levels, platelet counts and age. Further 
development of the potential role of miR-126 in the pathophysiology of CKD is 
necessary. In addition, this study did not examine the effect of maintenance 





Aims and hypotheses 
The overarching hypothesis for my thesis is that miRs are clinically relevant 
biomarkers for acute and chronic vascular dysfunction.  
 
Study 1 (Chapter 3): This study aimed to determine the potential application 
of miR-126 as a marker of acute vascular dysfunction in patients with ANCA 
vasculitis. The circulating concentration was compared in healthy volunteers 
and patients at disease presentation and once in clinically defined treatment-
induced remission. These results were then compared against currently used 
clinical measures of vascular health to determine the validity of miR-126 as a 
biomarker of vascular dysfunction in acute injury. We hypothesised that miR-
126 would be lower in disease and increase with treatment, reflecting the 
patient’s vascular health.  
 
Study 2 (Chapter 4): This study aimed to examine this association in chronic 
disease, specifically CKD and ESRD with haemodialysis. The concentration of 
circulating miR-126 in the patient cohorts was directly compared against 
clinical data which is used currently for diagnosis and patient evaluation. The 
hypothesis for this study was that miR-126 would have an inverse relationship 
with disease severity. In CKD, miR-126 would be low and the concentration 
would be further reduced in ESRD.  
 
Study 3 (Chapter 5): As ANCA vasculitis has a high relapse rate, this study 
aimed to identify potential circulating miR biomarkers, using small RNA 
sequencing, to identify disease relapse, in order to prevent additional vascular 
damage occurring. We hypothesised that patients with active disease would 
have a panel of differentially expressed miRs in comparison to treatment-
induced remission. 
 
Study 4 (Chapter 6): As miRs are known to be transported in circulation in 
ECVs, this study aimed to determine the role of the miRs as mediators of 
vascular dysfunction. We hypothesised that ECVs isolated from plasma 
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samples from patients with active vascular dysfunction would result in a 
heightened immune response in macrophages and renal damage in human 









All studies were approved by the local research ethics committee and 
performed in accordance with the Declaration of Helsinki.98 The study, entitled 
“MicroRNA signatures of disease activity in ANCA-associated vasculitis”, REC 
reference 13/ES/0126 (formerly 10/S1402/33) was approved by The Tissue 
Governance committee in June 2015. Informed consent was obtained from all 
participants. Patients presenting with ANCA vasculitis were recruited from the 
Vasculitis Service at the Royal Infirmary of Edinburgh. The subjects were aged 
18-80, male or female and were sero-positive for ANCA vasculitis and had 
organ-threatening disease, which required immunosuppression. Patients were 
considered sero-positive for MPO if their antibody level was > 5.0 IU/mL and 
PR3 positive with antibody levels > 3.0 IU/mL. All patients gave consent for 
inclusion in the study. In patients with ANCA vasculitis, data collected included 
demographics, disease activity and damage assessments, medications, co-
morbidities and laboratory results at each assessment and severe adverse 
events since starting treatment. 
 
Serum and plasma samples were collected at disease presentation and once 
deemed to be in treatment-induced remission, determined by the Birmingham 
vasculitis activity score (BVAS) scale (Table 3).99-101 At disease presentation 
and remission, 2 EDTA plasma (9 ml each) and 2 serum (7.5 ml each) blood 
samples were collected from each subject. Pulse wave velocity (PWV) was 
measured in the clinic for a selection of patients. PWV is the gold standard 
measurement for quantifying arterial stiffness.   It is the velocity at which the 
pressure waves, which are  produced by systolic contractions of the heart,  
propagate the arterial tree.102 PWV gives an overall measurement of arterial 
stiffness, however, this measurement is influenced by factors including age, 
smoking and blood pressure,103 Measurements are conducted in a clinical 
setting by trained staff, therefore it is not always possible to measure it for 
every patient.  
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Plasma and serum samples are commonly used in clinical biomarker studies. 
Plasma samples were used for the biomarker studies due to its stability and 
reproducibility. Previous studies have demonstrated that results are more 
robust in biomarker studies using plasma, rather than serum.104  
 
Healthy volunteers 
Consent was obtained from all healthy volunteers for inclusion in the study. 
Consenting adults were recruited who reported no medical conditions and no 
medical complaints. In healthy volunteers, 1 EDTA plasma (9 ml each) and 1 
serum (7.5 ml each) blood sample were collected from each subject.  
 
Blood sample processing 
After blood samples were drawn, plasma and serum sample tubes were 
immediately centrifuged at 4oC for 15 minutes at 1100 x g. The centrifuge 
speed had an impact on the concentration of miRs measured in human blood 
(Figure 5). This was particularly evident for miR-126-3p and miR-126-5p as 
the miR concentrations were lower as the centrifuge speed increased. This is 
an important factor for biomarker studies as sample processing may result in 
incorrect findings due to technical variation. Once spun, the serum or plasma 
layers were removed and stored at -80oC. Freeze thawing was avoided in 
order to preserve sample integrity. 
 
Figure 5. Effect of centrifuge speed on miR concentrations in human blood samples.  
The concentration of miRs in blood spun at 2,000 x g and 1,100 x g were compared for a selection of 
miRs. 
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Category  Symptom Persistent New/worse 
General Myalgia 1 1 
Arthralgia/arthritis 1 1 
Fever ≥38oC 2 2 
Weight loss ≥2 kg 2 2 
Cutaneous Infarct 1 2 
Purpura 1 2 
Ulcer 1 4 
Gangrene 2 6 
Other skin vasculitis 1 2 
Mucous membranes / eyes Mouth ulcers 1 2 
Genital ulcers 1 1 
Adnexal inflammation 2 4 
Significant proptosis 2 4 
Scleritis/Episcleritis 1 2 
Conjunctivitis/Blepharitis/Keratitis 1 1 
Blurred vision 2 3 
Sudden visual loss 
 
6 





Ear, nose and throat Bloody nasal 
discharge/crusts/ulcers/granulomata 
2 4 
Paranasal sinus involvement 1 2 
Subglottic stenosis 3 6 
Conductive hearing loss 1 3 
Sensorineural hearing loss 2 6 
Chest Wheeze 1 2 
Nodules or cavities 
 
3 
Pleural effusion/pleurisy 2 4 
Infiltrate 2 4 
Endobronchial involvement 2 4 
Massive haemoptysis/alveolar haemorrhage 4 6 
Respiratory failure 4 6 
Cardiovascular Loss of pulses 1 4 
Valvular heart disease 2 4 
Pericarditis 1 3 
Ischaemic cardiac pain 2 4 
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Cardiomyopathy 3 6 
Congestive cardiac failure 3 6 
Abdominal  Peritonitis 3 9 
Bloody diarrhoea 3 9 
Ischaemic abdominal pain 2 6 
Renal Hypertension 1 4 
Proteinuria >1+ 2 4 
Haematuria ≥10 RBCs/hpf 3 6 
Creatinine 125-249µ/L (1.41- 2.82mg/dl)* 2 4 
Creatinine 250-499 µ/L (2.83- 5.64mg/dl)* 3 6 
Creatinine ≥500 µ/L (≥5.66mg/dl)* 4 8 
Rise in serum creatinine >30% or fall in 
creatinine clearance >25% 
 
6 
*Can only be scored on the first assessment 
  
Nervous system Headache 1 1 
Meningitis 1 3 
Organic confusion 1 3 
Seizures (not hypertensive) 3 9 
Cerebrovascular accident 3 9 
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Spinal cord lesion 3 9 
Cranial nerve palsy 3 6 
Sensory peripheral neuropathy 3 6 
Mononeuritis multiplex 3 9 
Other As required 
  
 
Table 3. BVAS scale for defining active vasculitis. 




Plasma and serum samples (50μL) underwent RNA extraction using the 
miRNeasy serum/plasma kit (Qiagen, Venlo, Netherlands). The 
manufacturer’s instructions were followed. After thawing, 50L of the 
serum/plasma sample was diluted with 150L RNase free water. Five times 
the volume (1mL) of Qiazol lysis reagent was added and mixed by vortexing 
before incubating at room temperature (15 – 25°C) for 5 minutes. A spike-in 
exogenous control was added, 3.5L of C. elegans miR-39, at 1.6 x 108 
copies/L. Following this, 200L chloroform was added before shaking the 
sample to mix and incubating at room temperature for 3 minutes. The samples 
were centrifuged for 15 min at 12,000 x g at 4°C. The upper aqueous phase 
was removed and mixed with 1.5 volumes of 100% ethanol. The samples were 
passed through a RNeasy MinElute spin column at ≥ 8000 x g for 15 s at room 
temperature. The column was then rinsed with 700L Buffer RWT and 
centrifuged for 15 s at ≥ 8000 x g. This was repeated with 500L Buffer RPE, 
a mild washing buffer. The column was then rinsed with 500L of 80% ethanol 
for 2 min at ≥ 8000 x g. The column was dried, and the RNA was eluted in 
14L RNase-free water by spinning for 1 minute at full speed. Eluted RNA was 
stored at -80oC until required.  
 
Reverse transcription PCR 
After RNA extraction, 5L of each elute was reverse transcribed into cDNA 
with a single-step cDNA synthesis reaction using the miScript II RT Kit 
(Qiagen, Venlo, Netherlands). The manufacturer’s instructions were followed. 
The template RNA was thawed on ice. The reverse transcription master mix 
was prepared as detailed in Table 4. The RT master mix contained all 
necessary components for first-strand cDNA synthesis except the template 
RNA. The miScript buffer varied depending on whether the template RNA was 
from mRNA or miR as the reaction was optimised for each specific starting 
material. For each reaction, 5L of RNA template was mixed with the RT 
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master mix. To reverse transcribe the product, the samples were incubated at 
37oC for 60 minutes followed by 95oC for 5 minutes to inactivate the miScript 
Reverse Transcriptase. The cDNA was then diluted 10-fold in nuclease-free 
water and stored at -20oC until required.  
 
Component Volume/reaction 
5x miScript HiSpec Buffer (for miRs) 
5x miScript HiFlex Buffer (for mRNAs) 
4L 
10x miScript Nucleics Mix 2L 
RNase-free water 7L 
miScript Reverse Transcriptase Mix 2L 
Template RNA 5L 
Total volume 20L 
Table 4. miScript master mix components for reverse transcription. 
 
Quantitative PCR 
The diluted cDNA was used for quantitative PCR (qRT-PCR) with the miScript 
SYBR Green Kit (Qiagen, Venlo, Netherlands) using the components listed in 
Table 5. A master mix was prepared for each primer (detailed in the results 
chapters) and dispensed into a 384 well white plate. Following this, 1L of the 
template cDNA was added to each well and the plate was centrifuged in a 
bench-top centrifuge at 1500 x g for 2 minutes at room temperate.  
 
Component  Volume/reaction 
2x QuantiTect SYBR Green PCR Master Mix 5L 
10x miScript Universal Primer 1L 
10x miScript Primer Assay  1L 
RNase-free water 2L 
Template cDNA 1L 
Total volume 10L 
Table 5. Master mix components for miScript SYBR Green qPCR reaction. 
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Real-time PCR was carried with a Light Cycler 480 (Roche, Basel, 
Switzerland) using the recommended miScript cycling conditions for 45 cycles, 
shown in Table 6. Data collection was performed at the extension step for each 
qRT-PCR run and the cycle threshold (Ct) value was recorded for each sample 
in duplicate. In addition, dissociation curve analysis was performed for the 
PCR products to verify the primer specificity.  
 
Step Time Temperature 
PCR Initial activation step 15 minutes 95oC 
3-step cycling   
Denaturation 15 seconds 94oC 
Annealing 30 seconds 55oC 
Extension 30 seconds 70oC 
Table 6. Cycling conditions for qPCR using the Qiagen miScript SYBR Green PCR kit. 
 
Relative quantification 
MiR expression was analysed using the Ct method.105 A C. elegans miR 
mimic was used as a spiked-in control. This allowed for the Ct values for the 
miRs of interest to be normalised to the spiked-in control. The data obtained 
were translated by the 2-Ct method. 
 
Absolute quantification 
To measure the expression of the miRs of interest, absolute quantification was 
performed. The concentrations of the miRs of interest were determined by 
measuring the Ct values for miR mimics at known concentrations, using serial 
dilutions, by qRT-PCR. From this, a standard curve was prepared to compare 
the Ct values for the miRs of interest. This process was carried out for miR-




Figure 6. Standard curves from miRs of interest. 
(A) miR-122 and (B) miR-126 standard curves for absolute quantification in patient samples. The solid 
blue line shows the semilog and the dotted line shows the 95% confidence interval (CI). 
 
Data and statistical analyses 
Data were stored and statistically analysed using GraphPad Prism 8 software 
(La Jolla, California, United States) unless stated otherwise. For NTA results, 
data from three triplicate videos were analysed by calculating the AUC for 
particles sized between 20-100nm. Throughout, unless otherwise stated, a 
Wilcoxon test was used for paired samples and for unpaired samples, a Mann-
Whitney test. For correlations, normality tests were performed (D'Agostino-
Pearson omnibus test) in order to establish the distribution, followed by either 
a Pearson or Spearman test for the significance. Unless otherwise stated, data 
were expressed as mean ± standard deviation (SD) and P < 0.05 were seen 
as significant throughout. Alternative methods of statistical analysis employed 
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Vascular dysfunction and kidney disease commonly co-exist, and their 
presence substantially increases the risk of CVD. ANCA vasculitis is a rare 
disease, primarily affecting the vasculature, which often causes renal injury, 
resulting in rapidly progressive glomerulonephritis. It represents a tractable 
model of acute vascular and renal injury in humans. It is an inflammatory 
disorder characterised by leucocyte infiltration and necrosis of the small 
arteries. Even with current treatment strategies, the survival rate after the 
diagnosis of AAV is lower in comparison to unaffected cohorts with a 2.6 
mortality ratio, with more deaths observed than expected, when compared to 
age and sex-matched counterparts,18, 19, 106 with many patients suffering 
chronic inflammation, a major contributor to the development and progression 
of both CVD107 and CKD.20 Furthermore, those who respond to treatment 
remain at risk of further disease relapses108 and organ damage. 
 
There is an unmet clinical need for biomarkers that specifically report vascular 
health and injury. In vasculitis, it is a clinical challenge to evaluate the level of 
vascular damage and the response to treatment. In AAV patients with renal 
involvement, the measurement of renal function using serum creatinine is often 
inadequate because a high degree of renal damage can occur before renal 
function is impaired to a detectable level.109 Although serum creatinine may 
decrease with treatment, inflammation can potentially continue even after 
renal function has improved. Biomarkers that can specifically report small 
vessel damage would allow for early therapeutic interventions, as well as help 
to detect patients at risk of disease relapses. 
 
The miR that was evaluated in this study, miR-126, is endothelial cell-enriched 
and present throughout the vasculature. miR-126 is located in the 7th intron of 
the EGFL7 gene, which encodes a secreted inhibitor of smooth muscle cell 
migration, on chromosome 9 in humans.110 It has an established role as a 
regulator of vascular integrity and angiogenesis.111 Circulating miR-126 has 
been described as a potential biomarker for vascular disorders such as 
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diabetes112, 113 and myocardial infarction114, with lower circulating 
concentrations being associated with disease and poor vascular prognosis.115 
Low levels of miR-126 causes reduced vessel formation due to the modulation 
of endothelial cells to vascular growth factors and leucocyte adhesion.116 Due 
to its known role in vascular integrity and endothelial cell enrichment, miR-126 
is an attractive biomarker in acute vascular injury. It is also well established as 




Aims and hypothesis 
The hypothesis for this chapter was that miR-126 was a biomarker of vascular 
integrity in the circulation and that it would be altered by vascular injury. miR-
126 would track treatment-induced improvement in vascular function in acute 
injury in patients with ANCA vasculitis. This study aimed to determine the 
circulating concentration of miR-126 in healthy volunteers and patients with 
vasculitis. The concentration of miR-126 was measured in vasculitis patients 
with active disease and treatment-induced remission. These results were 







To estimate the healthy reference interval for circulating miR-126 consenting 
adults were recruited who reported no medical conditions and no medical 
complaints. Blood was drawn under normal conditions. In healthy volunteers, 
3 EDTA plasma (2.7mL each) and 3 serum (4.9mL each) blood samples were 
collected from each individual.  
 
For this study, 130 individuals were recruited. This included 60 healthy 
volunteers and 70 patients with AAV. Patients were recruited from the 
Vasculitis Service at the Royal Infirmary of Edinburgh, UK. The inclusion 
criteria for this study were patients who presented with sero-positivity for ANCA 
vasculitis, as defined by ANCA antibody titres. Patients were considered sero-
positive for MPO if their antibody level was > 5.0 IU/mL and PR3 positive with 
antibody levels > 3.0 IU/mL There were no defined exclusion criteria for this 
study. Plasma and serum samples were used from patients at entry into the 
study and at a subsequent follow-up visit when the condition was considered 
to be at the remission stage after successful treatment. Samples were taken 
with consent and stored immediately at -80oC after being spun in a workbench 
centrifuge at 1,100 x g for 10 minutes at 4oC. The study was approved by the 
local research ethics committee and performed in accordance with the 
Declaration of Helsinki. Informed consent was obtained from all participants. 
The study, entitled “MicroRNA signatures of disease activity in ANCA-
associated vasculitis”, REC reference 13/ES/0126 (formerly 10/S1402/33) was 
approved by The Tissue Governance committee in June 2015. Clinical data 
were obtained by clinical staff at the Edinburgh Renal Unit at the Royal 




Plasma samples (50μL) underwent RNA extraction using the miRNeasy 
serum/plasma kit (Qiagen, Venlo, Netherlands). Further details are given in 
Chapter 2.  
 
Reverse transcription PCR 
After RNA extraction, 2.5μl of each elute was reverse transcribed into cDNA 
using the miScript II RT Kit (Qiagen, Venlo, Netherlands). The manufacturer’s 
instructions were followed. The cDNA was then diluted 10-fold in nuclease-
free water.  
 
Quantitative PCR 
The diluted cDNA was used for qRT-PCR with miScript SYBR Green Kit 
(Qiagen, Venlo, Netherlands). Real time PCR was carried with a Light Cycler 




Statistical analysis was performed using GraphPad Prism 8 software. For 
paired samples, a Wilcoxon test was used and for unpaired samples, a Mann-
Whitney test. For correlations, normality tests were performed (D'Agostino-
Pearson omnibus test) in order to establish the distribution, followed by either 







Patient’s clinical characteristics 
For this study, 70 patients with active vasculitis were recruited and followed 
up. Clinical measurements of the patient’s kidney, liver and inflammatory 
status were recorded pre-treatment, at initial disease presentation, and post-
treatment, once remission had been achieved (Table 7). Renal function 
improved after treatment as determined by creatinine and eGFR. There was 
an improvement in liver function for ALP and GGT, however, there was no 
change for ALT. Additionally, CRP was reduced greatly post-treatment, 
however, albumin and haemoglobin slightly increased.
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Table 7. Clinical data for vasculitis patients pre- and post-treatment.  
The data are shown as mean ± SD with range. Significance of numerical data between groups was ascertained using a 2-tailed paired t-test.  
Characteristics Pre-treatment (n = 70) Post-treatment (n = 70) P value 
Age, years 62 ± 14 (27 - 82) - - 
Sex, M/F 43/27 - - 
Organs involved 2 ± 1 (1 - 6) - - 
- Kidney 44 - - 
- Lung 33 - - 
- ENT 17 - - 
- Nerve 13 - - 
- Eyes 9 - - 
eGFR, mL/min/1.73m2 46 ± 34 (4 - 124) 57 ± 29 (9 - 121) 0.04 
Serum creatinine, mol/L 200 ± 177 (54 - 962) 150 ± 144 (64 - 1000) 0.03 
ALT, U/L 20 ± 15 (6 - 83) 20 ± 10 (4 - 48) 0.94 
ALP, U/L 96 ± 62 (13 - 338) 67 ± 18 (39 - 122) 0.0002 
GGT, U/L 55 ± 44 (11 - 182) 33 ± 26 (10 - 148) 0.0009 
Albumin, g/L 28 ± 7 (14 - 41) 37 ± 4 (24 - 46) <0.0001 
CRP, mg/L 82 ± 75 (3 - 275) 6 ± 15 (0 - 108) <0.0001 
Haemoglobin, g/L 107 ± 23 (62 - 157) 124 ± 28 (2 - 170) <0.0001 
Urine protein:creatinine mg/mmol 141 ± 188 (0 - 948) 107 ± 146 (0 - 531) 0.82 
Urine creatinine, mol/24hrs 12 ± 20 (3 - 109) 8 ± 4 (3 - 20) 0.90 
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Circulating miR-126 concentration in AAV 
Plasma samples were obtained from healthy volunteers and patients with AAV 
pre- and post-treatment. The concentration of circulating miR-126 was 
measured for each cohort in order to ascertain its ability as a marker of acute 
vascular damage (Figure 7). A baseline measurement for miR-126 was 
obtained in the healthy control group. The data demonstrated that the healthy 
baseline concentration of miR-126 was substantially higher than for the AAV 
patient cohort pre-treatment. After the patients were deemed to be in 
treatment-induced remission, post-treatment, the concentration of miR-126 
increased. The data establish that miR-126 is higher in health and reduced 
with acute vascular dysfunction. Even after treatment, miR-126 does not 
increase to the normal concentration. 
 
 
Figure 7. Circulating miR-126 in acute vascular injury.  
The concentration of miR-126 in healthy volunteers (n = 60) and AAV patients (n = 70 paired) pre- and 
post-treatment. Bars show median with IQR, **p<0.01, ****p<0.0001 (Mann-Whitney test for 
unpaired analysis and Wilcoxon test for paired analysis). 
 
Circulating miR-126 in AAV subgroups 
To determine whether disease subclass influenced the circulating 
concentration of miR-126 in patients with AAV, the date was further analysed 
by clinical subgroups, as shown in Figure 8. This illustrated that for MPO and 
PR3, there was not a significant difference in miR-126 concentration between 
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the subtypes. This was also demonstrated in the analysis of AAV patients with 
renal involvement versus those without.  
 
 
Figure 8. Analysis of circulating miR-126 is AAV subgroups. 
The concentration of miR-126 in patients diagnosed as (A) MPO positive (n = 28) and PR3 positive (n = 
23) pre- and post-treatment. (B) Patients classified as having renal involvement (n = 44) and non-renal 
involvement (n = 11) pre- and post-treatment. Bars show median with IQR (Mann-Whitney test for 
unpaired analysis and Wilcoxon test for paired analysis). 
 
 
Evaluation of miR-126 as a biomarker in AAV 
The sensitivity and specificity of circulating miR-126 as a biomarker for AAV 
was quantified using receiver operating characteristic (ROC) curve analysis. 
The sensitivity and specificity were compared for healthy volunteers versus 
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pre-treatment patients (Figure 9A) and compared for patients pre-treatment 
versus post-treatment (Figure 9B). The AUC was measured for each analysis 
to evaluate miR-126 as a biomarker of disease. 
 
  
Figure 9. ROC curve analysis for miR-126 as a biomarker for AAV. 
Sensitivity and specificity for (A) healthy volunteers versus pre-treatment patients with active disease 
and (B) pre-treatment versus post-treatment. The ROC curve analysis demonstrates the area under the 
curve (AUC) and statistical significance. 
 
miR-126 as a marker of vascular damage 
PWV is the gold standard measurement for quantifying arterial stiffness. It is 
also an independent predictor of future adverse cardiovascular outcomes in 
patient groups117. PWV was measured pre- and post-treatment and the 
change in stiffness was evaluated against the change in circulating miR-126 
in a subgroup of AAV patients (Figure 10). There was a clear inverse 




Figure 10. Clinical measures of arterial stiffness correlate with circulating miR-126 in patients 
with AAV.  
The fold change in miR-126 has an inverse relationship with the change in arterial stiffness from pre- to 
post-treatment (n = 8). The red line shows the linear regression for the correlation. The change in PWV 
is the value pre-treatment minus the post-treatment value, expressed in m/s.  
 
miR-126 as a marker of renal function in AAV 
Vascular dysfunction commonly co-exists with kidney disease, which results 
in a substantially increased risk of cardiovascular disease. As renal damage is 
often a severe manifestation of AAV, renal function is measured at disease 
presentation, as well as follow-up appointments at the clinic. In order to 
ascertain the relationship between miR-126 and renal function during acute 
vascular injury, the clinical data were assessed (Figure 11). Creatinine had a 
weak negative correlation pre-treatment, and this was inverted to a positive 
correlation post-treatment. This was not reflected in the eGFR results, as no 
relationship was demonstrated in the AAV patient cohort. This suggests that 
miR-126 is not a biomarker of renal function.  
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C   
Creatinine Pre-treatment Creatinine Post-treatment eGFR Pre-treatment eGFR Post-treatment 
Analysis Spearman Pearson Pearson Spearman 
P-value 0.006 0.04 0.21 0.51 
r -0.37 0.28 0.17 0.09 
95% CI -0.58 to -0.10 0.01 to 0.51 -0.10 to 0.42 -0.19 to 0.36 
R squared - 0.08 0.03  
Number of pairs 54 55 54 54 
Figure 11. The concentration of circulating miR-126 in relation to clinical measures of renal function in patients with AAV. 
The solid red line shows the linear regression pre-treatment and dotted line for post-treatment. Individual patient data points are shown in black for pre-treatment and 
blue for post-treatment. (A) Creatinine demonstrates a weak negative relationship pre-treatment and a weak positive relationship post-treatment with circulating miR-
126, however, (B) eGFR does not correlate with miR-126. (C) Correlation analysis for creatinine and eGFR based on the normality of the data. 
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miR-126 does not correlate with systemic inflammation 
A major component of vascular damage in AAV is vascular inflammation. This 
is characterised by leucocyte infiltration into the target blood vessel and as a 
result, the endothelium is damaged. At disease presentation, and once in 
treatment-induced remission, clinical markers of inflammation are measured. 
The results of these tests were compared against circulating miR-126 (Figure 
12). The clinical markers measured were albumin, CRP and haemoglobin. 
These tests all provide information relating to systemic inflammation. Overall, 
there was no correlation between clinical tests and miR-126. There was a 

















Analysis Spearman Spearman Spearman Spearman Pearson Spearman 
P-value 0.20 0.43 0.18 0.55 0.92 0.04 
r 0.18 0.11 -0.19 -0.08 0.01 0.27 
95% CI -0.10 to 0.44 -0.17 to 0.37 -0.45 to 0.10 -0.35 to 0.20 -0.25 to 0.28 -0.001 to 0.51 
R squared - - - - 0.0002 - 
Number of pairs 53 54 51 55 54 55 
Figure 12. Clinical markers of systemic inflammation in AAV in relation to circulating miR-126. 
The solid red line shows the linear regression pre-treatment and dotted line for post-treatment. Individual patient data points are shown in black for pre-treatment and 
blue for post-treatment. (A) Albumin, (B) CRP and (C) Haemoglobin do not correlate with miR-126 pre-treatment in AAV. Post-treatment, miR-126 shows a slight 
positive correlation with haemoglobin. (D) Correlation analysis based on the normality of the data. 
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A liver enriched miR is unchanged in vasculitis 
A biomarker of vascular health must be specific and therefore non-vascular 
miRs should not be altered by disease state in AAV. Since an endothelial cell 
marker, miR-126, changed markedly after treatment in AAV, a liver enriched 
marker, miR-122, was measured in the patients (Figure 13). miR-122 was 
measured in the same vasculitis patient cohorts as described above. For AAV 
patients, the level of miR-122 was comparable pre- and post-treatment. The 
miR profile in these patients was not changed overall, suggesting that the 
change in miR-126 is specific, rather than the disease state altering the 
miRNome in circulation.  
 
 
Figure 13. Circulating miR-122, a marker of liver dysfunction, is not altered in AAV between active 
disease and remission. 
The concentration of miR-122 was measured in plasma samples in AAV patients pre- and post-treatment 





The risk of cardiovascular disease increases substantially in patients with 
vascular injury and kidney disease. Endothelial dysfunction often co-exists 
with cardiovascular disease, meaning that the development of a biomarker to 
report vascular health is required. This study examined the potential role of 
miR-126 as a circulating biomarker of vascular dysfunction in acute vascular 
dysfunction, specifically in ANCA vasculitis as a model of severe injury.  This 
study demonstrated that circulating miR-126 is at the highest concentration in 
healthy individuals and is reduced in vasculitis. After successful 
immunosuppression, the concentration of miR-126 increases, however, this is 
not to the same concentration range for healthy individuals, which may reflect 
their continuing vascular damage. These data were supported by the patient’s 
PWV results, the gold standard measurement for arterial stiffness. There was 
no clear relationship between miR-126 and clinical measures of kidney 
function or inflammatory status. Circulating miR-126 did not distinguish 
between AAV subclass or reflect whether there was renal involvement or not. 
This supported the hypothesis that miR-126 is a biomarker of vascular health 
and injury in patients with acute vascular dysfunction.  
 
This study demonstrated a significant correlation between treatment-induced 
changes in endothelial cell-enriched miR-126 and pulse wave velocity, a 
clinical measure of arterial stiffness that often co-exists with endothelial 
dysfunction.118 In contrast, there was no correlation between the change in 
miR-126 and changes in measures of renal injury/repair in those with ANCA 
disease. This was also the case for measures of inflammatory status in the 
patient cohort. Clinically, a circulating biomarker that reports vascular health 
could have widespread utility. Further studies would allow for miR-126 to be 
measured in a range of other systemic inflammatory disorders such as 
rheumatoid arthritis and systemic lupus erythematosus to ascertain the clinical 
potential as a biomarker.  
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Identifying ANCA vasculitis early and assessing its response to treatment 
remain important clinical challenges. In those with renal involvement, the 
measurement of renal function using serum creatinine is often inadequate 
because substantial renal damage can occur before function is impaired to a 
detectable extent.109 Furthermore, although serum creatinine may decrease 
with treatment, it remains unclear whether histological inflammation continues 
once renal function has stabilised. Additionally, currently there are no good 
measures of disease activity in those with extra-renal vasculitis alone. 
Biomarkers specific to small vessel inflammation would not only allow early 
implementation of appropriate treatments but also help identify those patients 
with grumbling disease activity despite therapy and potentially predict disease 
relapses. 
 
Identifying a reliable and sensitive biomarker to predict disease relapse 
remains an important research focus. Vasculitis often continues as a 
‘grumbling’ disease or results in a relapse of the disease even after treatment-
induced remission has been achieved. A study of 1,804 patients found that 
relapse occurred in 201 patients (38%) and 133 patients (25%) died.119 The 
study concluded that a creatinine level >200 μmol/L at disease presentation 
was associated with a lower rate of disease relapse. This is potentially a 
problematic approach as severe renal and vascular damage has occurred at 
this level. With a successful minimally invasive biomarker of vascular injury, it 
would be possible to track the disease progression to relapse and alter the 
treatment strategy appropriately in order to prevent further damage occurring.  
 
In clinical care, miR-126 represents a potential biomarker in ANCA vasculitis. 
From the FDA guidelines,75 as outlined in Chapter 2, a biomarker may have 
multiple definitions with validation and evidence available for each. This study 
suggests that miR-126 has the potential to clinically act as monitoring 
biomarker, as well as a prognostic biomarker. As a monitoring biomarker, miR-
126 could be used to assess the effect of a medical product, such as 
therapeutic interventions, in the treatment and maintenance of remission. 
 73 
Serial measurements could be performed to evaluate the effectiveness of the 
treatment strategy. To utilise it for this purpose, the minor changes in the 
concentration would need to be defined to understand the slight changes in 
the patient’s treatment responses. As a prognostic biomarker, miR-126 could 
be used to predict the probability of disease relapse or disease progression 
with pre-diagnosed ANCA vasculitis. In a clinical care setting, it allows for 
evaluation of the possible length of treatment for a patient or their length of 
stay in hospital.  
 
Limitations 
Alongside currently used markers of vascular health, and experimental 
approaches such as PWV, miR-126 has the potential to supplement the 
diagnosis of acute vascular dysfunction and response to treatment. One 
limitation of this study is the small cohort of patients that had PWV measured. 
It would have been optimal for all patients to have their arterial stiffness 
measured and compared before and after treatment, however, there was 
limited availability for this measurement. This would provide a more detailed 
relationship between the two measurements. In addition, ADMA, an 
endogenous inhibitor of nitric oxide synthase, was not measured in the 
vasculitis patient cohort. This is considered an independent risk factor of 
cardiovascular disease and therefore would give insight into the potential role 
of miR-126 as a biomarker of vascular health.  
 
A further limitation of this study is that the healthy controls that were included 
in this study were younger overall in comparison to the vasculitis group. In 
European studies, the mean age for AAV diagnosis is 60 years old120 with a 
peak prevalence for the disease between 65-74 years old.121 As many 
individuals aged 60 years and over have pre-existing medical conditions or 
taking regular mediation, it was not possible to age match the controls. It would 
have improved the clinical relevance of the study by having age-matched 
controls as it would have been beneficial to develop a healthy baseline range 
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in order to compare against the vasculitis patient’s results in active disease 




Previous studies have demonstrated that the circulating concentration of miR-
126 in healthy individuals is high. With vascular damage, the concentration is 
reduced. This study aimed to examine the potential of miR-126 as a biomarker 
of acute vascular dysfunction in a human model of the disease, AAV. miR-126 
was at a low level at disease presentation in ANCA vasculitis patients. After 
successful immunosuppression, treatment-induced remission was achieved 
and this increased the circulating concentration of miR-126 in the patient 
cohort, however, this was still not to the same level as the healthy baseline 
cohort. This may be representative of their continuing vascular damage as a 
result of the disease. miR-126 correlates with clinical measurements of 
vascular health, such as arterial stiffness. This suggests a role of miR-126 as 
a marker of vascular function. There was not a distinct relationship between 
other clinical measurements, consistent with its role as a marker of vascular 






Chapter 4 – miR-126 is a marker of 







CKD affects millions of people worldwide. Its incidence is growing 
exponentially, with the disease being responsible for more than 25 million 
deaths per year.122 The incidence of cardiovascular events is markedly higher 
in CKD patients than for the general population.123 CKD patients with stage 5 
of the condition are five times more likely to develop CVD than the general 
population. ESRD is diagnosed when the patient has between 10 to 15% of 
renal function remaining and they have progressed to the most severe form of 
CKD, requiring maintenance HD, or kidney transplantation.  
 
Currently, disease progression from CKD to ESRD, and the associated 
vascular disease, is monitored using parameters for renal and vascular 
function. The standard assessment of renal function involves measurement of 
serum creatinine concentration, blood urea, urinalysis and renal biopsy when 
indicated.124 ESRD patients have chronic vascular dysfunction and arterial 
stiffness, as demonstrated by measurement of arterial PWV. Increased PWV, 
and therefore stiffer arteries, in comparison to healthy controls, has been 
identified as an independent predictor of cardiovascular mortality in this patient 
cohort.125, 126 Studies have demonstrated that this is also the case for CKD 
patients, even with mild to moderate renal impairments.127 Arterial stiffness 
increases with disease severity and CKD stage.128, 129   
 
There is an unmet clinical need for biomarkers that specifically report vascular 
health in chronic renal disease to enhance early diagnosis, prognosis and 
monitor response to treatment. The optimal biomarker should be minimally 
invasive, sensitive, specific and stable. A significant emerging class of 
biomarker are miRs. They can be relatively organ-specific, and they can be 
used in a pre-clinical setting as well as being translated for use in patients 
because their sequence is conserved across species. Currently no known 
miRs are able to diagnose specific forms of renal disease.130 Many studies 
have attempted to define appropriate biomarkers of renal injury in large patient 
cohorts. miR-126 has a crucial role in vasculature formation,91, 131 
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inflammation132 and endothelial stress response.92 It is enriched in endothelial 




Aims and hypothesis 
The hypothesis for this chapter is that miR-126 will be at a low circulating level 
in CKD. For patients with ESRD, miR-126 will be at a lower level than moderate 
CKD. This would reflect the vascular damage for each patient group. This 
study aims to assess the circulating levels of miR-126 in healthy controls, 
patients with CKD and ESRD. miR-126 will be measured in ESRD patients 
before and after a session of haemodialysis to examine the effect on miR 
levels. This will be evaluated in comparison to clinical data obtained as 






For this study, 105 individuals were recruited. This included 60 healthy 
volunteers (as described in Chapter 3), 30 patients with moderate CKD and 15 
patients with stable ESRD on maintenance HD from the outpatient dialysis unit 
at the Royal Infirmary of Edinburgh, UK. The study was approved by the local 
research ethics committee and performed in accordance with the Declaration 
of Helsinki. Informed consent was obtained from all participants.  
 
ESRD patients 
ESRD patient samples were taken from a previously published study133. The 
inclusion criteria for ESRD patients were that they were age 18 years or over 
and being treated with HD for more than 3 months. All of the included patients 
were treated with HD three times per week for 4-5 hours per session. The data 
collected included patient demographics, cause of ESRD, duration of dialysis 
and current medications.  
 
CKD patients 
Patients with CKD stages I–V (estimated glomerular filtration rate 7–57 
ml/min/1.73m2 calculated using the MDRD equation) were included. Briefly, 
subjects were recruited from the renal outpatient clinic at the Royal Infirmary 
of Edinburgh. The inclusion criteria were male or female CKD patients age 18 
years or over with an eGFR of <60 and not undergoing dialysis treatment. 




In healthy subjects and CKD patients, blood was collected in EDTA plasma 
tubes and centrifuged at 1,100 x g for 15 min at 4°C and then immediately 
frozen at -80°C. Two blood plasma samples were collected from each HD 
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patient, one immediately before and one after a single dialysis session, directly 




For paired samples, a Wilcoxon test was used and for unpaired samples, a 
Mann-Whitney test. For correlations, normality tests were performed in order 
to establish the distribution, followed by either a Pearson or Spearman test for 






A cohort of 30 male and female patients with varying degrees of CKD and 15 
age-matched patients with ESRD undergoing maintenance HD were recruited 
into this study. The patient’s demographic characteristics are shown in Table 
8. There was some variation between groups for gender. Kidney and liver 
function data are presented with more severe disease in the ESRD (pre-HD) 
group, which conforms to the expected disease phenotype.
 83 
 
Characteristics CKD (n = 30) Pre-HD (n = 15) Post-HD (n = 15) 
Age, years 59.8 ± 15.6 (26 - 82) 58.9 ± 12.14 (34 - 82) - 
Sex, M/F 21/9 8/7 - 
eGFR, mL/min/1.73m2 24.48 ± 14.12 (7 - 57) 8.00 ± 2.89 (2 - 12) 28.15 ± 10.74 (13 - 53) 
Serum creatinine, mol/L 216.97 ± 133.01 (76 - 654) 660.46 ± 199.15 (360 - 1067) 225.00 ± 79.98 (97 - 426) 
ALT, U/L 19.48 ± 8.44 (9 to 50) 14.54 ± 6.12 (7 - 25) - 
ALP, U/L 97.24 ± 37.82 (40 - 182) 100.39 ± 42.66 (52 to 178) - 
CRP, mg/L 5.25 ± 2.36 (2 - 7) 14.44 ± 20.68 (2 to 77) - 
Haemoglobin, g/L 123 ± 16 (83 - 160) 122 ± 12.51 (94 - 139) - 
Table 8. Clinical data obtained for CKD patients and ESRD patients pre- and post-haemodialysis (HD). 
The data are shown as mean ± SD with range.  
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Circulating miR-126 in patients with CKD 
Plasma samples were obtained from healthy volunteers and patients with renal 
disease. In the patient samples, the concentration of miR-126 was measured 
(Figure 14). A baseline for healthy volunteers was obtained from individuals 
without renal dysfunction or cardiovascular disease. For patients with 
moderate CKD, the mean was lower than for healthy volunteers. In ESRD 
patients, the circulating concentration of miR-126 was substantially lower than 
in moderate CKD and health. The concentration increased after a single 
session of maintenance haemodialysis. Even after dialysis, the concentration 
of miR-126 did not increase to the same concentration as moderate CKD or 




Figure 14. Circulating miR-126 in chronic kidney disease and ESRD. 
The concentration of miR-126 in healthy volunteers (n = 60), CKD patients (n = 30) and ESRD patients 
(n = 15) pre- and post-haemodialysis (HD). Bars show median with IQR, ***p<0.001, ****p<0.0001 
(Mann-Whitney test for unpaired analysis and Wilcoxon test for paired analysis). 
 
Clinical measures of vascular health correlate with circulating miR-126 
in moderate CKD 
Clinically, measuring vascular health is an essential parameter to determine a 
patient’s overall cardiovascular risk. For patients with CKD, there was a range 
of plasma miR concentrations, which may reflect differences in vascular health 
across patients. miR concentrations were correlated against a range of well-
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recognised measures of vascular function. Consistent with the data from 
patients with ANCA vasculitis, miR-126 correlated strongly with PWV (Figure 
15). In addition, miR-126 associated with circulating asymmetric 
dimethylarginine (ADMA). Low levels of these markers suggest vascular 






Analysis Pearson Spearman 
P-value 0.0002 0.0005 
r -0.58 -0.54 
95% CI -0.76 to -0.31 -0.74 to -0.26 
R squared 0.33 - 
Number of pairs 37 37 
Figure 15. Clinical measures of cardiovascular health correlate with circulating miR-126 in 
patients with moderate CKD.  
Red line shows the linear regression for correlations. (A) ADMA and (B) PWV inversely correlated with 
miR-126 in CKD patients. (C) Correlation analysis for ADMA and PWV based on the normality of the 
data. 
 
Circulating miR-126 and clinical measures of renal function 
After establishing the circulating concentration of miR-126 in renal patients and 
healthy volunteers, I examined the relationship between currently used clinical 
parameters for renal function in patients with CKD. In the CKD patient cohort, 
renal function was recorded at the clinic on the day that the plasma sample 
was taken for this study. The relationship between circulating miR-126 and 
currently used measures of renal function was examined (Figure 16). There 
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was no correlation between creatinine and miR-126, however, eGFR had a 
positive relationship. For higher levels of eGFR (a marker of renal function), 






Analysis Spearman Pearson 
P-value 0.07 0.01 
r -0.35 0.52 
95% CI -0.65 to 0.04 0.15 to 0.77 
R squared  -  0.27 
Number of pairs 28 24 
Figure 16. Clinical measures of human renal function in patients with moderate CKD in relation 
to miR-126.  
Red line shows the linear regression for correlations. (A) Creatinine does not demonstrate a clear 
relationship with miR-126 however, (B) eGFR correlates with miR-126 in CKD patients. (C) Correlation 
analysis for creatinine and eGFR based on the normality of the data. 
 
miR-126 as a marker of systemic inflammation in CKD 
Clinically, markers of systemic inflammation are measured in patients with 
CKD. To determine whether miR-126 was a marker of inflammation in this 
patient cohort, the clinical results were compared with the miR-126 
concentration (Figure 17). Albumin is a commonly measured parameter for 
systemic inflammation as inflammation reduces its rate of synthesis134.  
Albumin is also lost in nephrotic syndrome and produced less in liver disease 
and malnutrition. It had a positive correlation with miR-126 in CKD patients. 
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Conversely, there was no correlation between miR-126 and haemoglobin, a 






Analysis Spearman Pearson 
P-value 0.004 0.11 
r 0.51 0.30 
95% CI 0.17 to 0.75 -0.07 to 0.60 
R squared - 0.09 
Number of pairs 29 29 
Figure 17. Inflammation markers in circulation for patients with moderate CKD in relation to miR-
126.  
Red line shows the linear regression for correlations. (A) Albumin correlates with miR-126, however, (B) 
haemoglobin does not demonstrate a clear relationship with miR-126 in CKD patients. (C) Correlation 
analysis for albumin and haemoglobin based on the normality of the data. 
 
miR-126 as a marker of renal function in ESRD 
By definition, patients undergoing HD for ESRD have significantly impaired 
renal function in comparison to a healthy cohort and patients with moderate 
CKD. Two routinely used markers for renal function, creatinine and eGFR were 
evaluated with miR-126 pre- and post-HD (Figure 18). Creatinine levels did not 
correlate with miR-126 concentration pre-HD, however, there was a trend 
towards a relationship for post-HD. These results are similar for eGFR with no 




Creatinine Pre-HD Creatinine Post-HD eGFR Pre-HD eGFR Post-HD 
Analysis Pearson Spearman Pearson Pearson 
P-value 0.93 0.04 0.83 0.04 
r -0.03 0.57 -0.07 -0.57 
95% CI -0.57 to 0.53 0.01 to 0.86 -0.60 to 0.50 -0.85 to -0.02 
R squared 0.001 - 0.004 0.32 
Number of pairs 13 13 13 13 
Figure 18. Circulating miR-126 in relation to clinical measures of renal function in patients undergoing maintenance HD for ESRD.  
The solid red line shows the linear regression pre-HD and dotted line for post-HD. Individual patient data points are shown in black for pre-HD and blue for post-HD. Pre-
HD, (A) creatinine and (B) eGFR do not demonstrate a clear relationship with miR-126, however, there is a positive correlation for creatinine and inverse correlation for 
eGFR post-HD in CKD patients. (C) Correlation analysis for creatinine and eGFR based on the normality of the data.
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Blood pressure is altered with HD treatment in ESRD patients 
It is well established that hypertension is considered an independent risk factor 
for CKD progression to ESRD. Previous studies have attempted to examine 
the role of the endothelium in vascular dysfunction with hypertension. As 
patients with impaired renal function are likely to have issues with blood 
pressure regulation, we compared ESRD patient’s blood pressure immediately 
before the HD session and after it (Figure 19). This was compared against the 
concentration of miR-126 in the circulation. For systolic blood pressure (SBP), 
there was no correlation pre-HD, however, there was a notable inverse 
correlation post-HD in matched patients. Conversely, there was no correlation 





SBP Pre-HD SBP Post-HD DBP Pre-HD DBP Post-HD 
Analysis Pearson Pearson Pearson Pearson 
P-value 0.32 0.007 0.70 0.48 
r -0.33 -0.76 0.13 -0.24 
95% CI -0.78 to 0.33 -0.93 to -0.29 -0.51 to 0.68 -0.73 to 0.42 
R squared 0.11 0.57 0.02 0.06 
Number of pairs 11 11 11 11 
Figure 19. Circulating miR-126 in relation to blood pressure measurements in patients undergoing maintenance HD for ESRD.  
The solid red line shows the linear regression pre-HD and dotted line for post-HD. Individual patient data points are shown in black for pre-HD and blue for post-HD. (A) 
SBP does not correlate pre-HD, however, there is an inverse relationship following the treatment. (B) DBP does not demonstrate a clear relationship with miR-126 pre- or 
post-HD. (C) Correlation analysis for SBP and DBP based on the normality of the data. 
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miR-126 is not a marker of systemic inflammation in ESRD 
Inflammatory markers are routinely measured in ESRD patients undergoing 
maintenance HD. We compared two of these markers, before the HD session, 
with the plasma concentration of miR-126 (Figure 20). CRP is a routinely 
measured marker of chronic inflammation and this did not show a correlation 
with miR-126. Similarly, haemoglobin, a marker of systemic inflammation, did 






Analysis Spearman Pearson 
P-value 0.50 0.82 
r -0.20 -0.069 
95% CI -0.69 to 0.41 -0.60 to 0.50 
R squared - 0.005 
Number of pairs 13 13 
Figure 20. Inflammation markers in circulation for patients with ESRD undergoing maintenance 
HD in relation to circulating miR-126.  
Red line shows the linear regression for correlations. (A) CRP and (B) haemoglobin do not correlate with 
miR-126 in ESRD patients. (C) Correlation analysis for CRP and haemoglobin based on the normality of 
the data. 
 
Liver enriched miRs are downregulated in ESRD 
In order to determine whether the increase in miR concentration after dialysis 
was specific to endothelial cell-enriched miRs, a well characterised liver 
specific miR was measured (Figure 21). miR-122 was measured in the same 
patient cohorts as described above. Healthy volunteers and CKD patients had 
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comparable levels of circulating miR-122, however, this was reduced in ESRD 
pre-HD. With paired samples, post-HD, the concentration of miR-122 
significantly increased. 
 
Figure 21. Circulating miR-122, a marker of liver dysfunction in health, CKD and ESRD.  
The concentration of miR-122 was lower in ESRD and increases with HD. miR-122 was measured in 
plasma samples in healthy volunteers (n = 60), CKD patients (n = 30) and ESRD patients (n = 15) pre- 
and post-HD. Bars show median with IQR, **p<0.01, ****p<0.0001 (Mann-Whitney test for 




Endothelial dysfunction is often a precursor for future cardiovascular events, 
therefore determining an appropriate biomarker to track this is essential. This 
study demonstrated that circulating miR-126 is highest in healthy individuals 
and is lower in patients with reduced renal function. In ESRD, miR-126 is lower 
than for moderate CKD, and the concentration increases following 
maintenance HD, therefore a reflection of the patient’s vascular phenotype. 
This corresponds with gold-standard measures of vascular health, including 
PWV and ADMA. This suggests that miR-126 has a potential role in reporting 
vascular health and injury in human cohorts with chronic vascular dysfunction, 
including CKD and ESRD. In contrast, there was not a clear relationship 
implicating miR-126 as a biomarker of inflammation, blood pressure or the 
functional capacity of the kidneys. 
 
Clinical importance of miR-126 as a biomarker of vascular integrity 
Previous studies have suggested that HD will reduce the concentration of 
certain miR species. Potentially, this could be a consequence of miR clearance 
in the dialysate fluid.135 However, in patients with CKD, the total circulating miR 
concentration is reduced.133 This has previously been demonstrated by Neal. 
et al. They concluded that this was due to a global reduction in circulating miRs 
as a result of increased RNase activity in CKD patient’s blood.136 The findings 
of this study are consistent with this as miR-126 and liver enriched miR-122 
were both reduced pre-HD and increased after treatment. Further studies to 
directly measure the RNAse activity in the samples would allow for additional 
conclusions to be drawn about this hypothesis.  
 
Recent studies have demonstrated that miR-126 is at a lower level in 
circulation in CKD patients.97, 137 After HD, the concentration of miR-126 
increases which could suggest an improvement in vascular health, or 
alternatively, acute vascular damage caused by the HD procedure. 
Haemodialysis is an invasive procedure which will cause localised endothelial 
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cell disruption. A study by Kosch et al. detailed the effect of HD on acute 
vascular damage in a cohort of ESRD patients.138 They demonstrated that 
haemodialysis did not have a direct effect on endothelial function acutely. This, 
therefore, suggests that the increase in miR-126 after maintenance HD could 
potentially be the result of improved vascular function. 
 
This study suggests that in moderate CKD, miR-126 inversely correlates with 
a currently used clinical measure of vascular integrity and cardiovascular risk, 
ADMA. ADMA is an inhibitor of NO synthase and subsequent reduction in NO 
availability.139, 140 Clearance of ADMA during haemodialysis may have a 
beneficial role in vascular health by reducing the inhibition of NO synthase, 
and thus improve vascular integrity.138  
 
Additionally, this study demonstrated that miR-126 inversely correlated with 
PWV, the gold standard measure of arterial stiffness. This is an independent 
predictor of cardiovascular mortality in mild to moderate CKD.127 Arterial 
stiffness increases as CKD progresses in severity and stage.128, 129 This 
supports the potential for miR-126 to act as a biomarker in patients with 
impaired renal function and chronic vascular damage.  
 
Renal function was measured in patients with CKD and ESRD. For creatinine, 
a measurement of the kidney’s filtration efficiency, there was not a detectable 
correlation with miR-126. Interestingly, the CKD cohort exhibited a correlation 
with miR-126 and eGFR. eGFR is calculated using the MDRD equation, which 
is calculated based on the serum creatinine concentration, age, sex and 
ethnicity. This suggests that there are perhaps demographic factors which may 
influence the concentration of miR-126 in patient cohorts. ESRD patients had 
inverted results in comparison to CKD patients for renal function. This is 
indicative of the patient’s diminished renal function for this extreme phenotype 
of renal and vascular dysfunction.  
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This study did not find any definitive relationships between the concentration 
of miR-126 and general measures of patient health. For inflammation, there 
was some correlation between albumin and miR-126, however, this was not 
apparent for haemoglobin in CKD and there was not a correlation for 
haemoglobin or CRP in ESRD, pre- or post-HD. This suggests a degree of 
specificity for reporting vascular health and injury, rather than a general marker 
of chronic inflammation or disease. 
 
Limitations 
The results of this study suggest that miR-126 potentially has a role as a 
biomarker of vascular integrity. It shows an inverse correlation with clinical 
markers of vascular health. A limitation of this study is the absence of PWV 
and ADMA measurements for the ESRD groups. By obtaining these data, it 
would be possible to link the vascular health of patients with CKD and ESRD, 
and the subsequent changes in vascular health following HD. This would allow 
for a direct comparison of disease severity, and stage, in relation to the 
obtained miR-126 correlations. 
 
In addition, as this study was focused on clinical samples from patients, there 
is a high level of variation, due to the heterogeneity of the disease. By 
increasing the size of the patient cohorts, it would be possible to define a 








In health, miR-126 is at a high level and with vascular injury, there is a reduced 
concentration in circulating blood. In this study, we evaluated this in patients 
with moderate CKD and those with ESRD undergoing maintenance HD. miR-
126 is lower in CKD patients in comparison to health and this is further reduced 
in patients with ESRD. After a single session of HD, the concentration of miR-
126 increases, however, this is not to a near health level, reflecting their 
vascular health. miR-126 correlates with clinical measurements of vascular 
health, such as arterial stiffness. For CKD and ESRD patients, there is no clear 
relationship between other clinical measurements, confirming its role as a 


















Chapter 5 – Small RNA sequencing 





Studies have demonstrated roles for miRs in the pathogenesis of multiple 
cardiovascular diseases.141 Circulating miRs are potentially a reservoir for 
biomarker discovery as they provide insights into the complex regulatory 
functions of the tissue of origin.81 They are considered stable in circulation as 
they are able to avoid degradation by endogenous RNase activity.85 Due to 
miRs role in the negative interference of post-transcriptional gene regulation, 
they have potential as novel biomarkers for health and disease, as well as 
therapeutic targets.142, 143  
 
Many studies have reported the importance of miRNome small RNA 
sequencing to track disease progression and treatment monitoring.144, 145 
Technologies such as small RNA sequencing have allowed for the screening 
and discovery of a large amount of differentially expressed miRs that are 
involved in the development of cardiovascular disease.146, 147 From this, it is 
possible to identify and target these miRs for development of novel biomarkers 
of disease.  
 
ANCA vasculitis is a term used to describe a spectrum of conditions.148 These 
include GPA (formerly known as Wegener's granulomatosis), MPA and EGPA 
(formerly known as Churg-Strauss syndrome). The disease manifestations of 
GPA and MPA are variable at presentation but both primarily cause small 
vessel inflammation and damage. There is a high degree of variation in terms 
of disease severity in vasculitis. Substantial disease heterogeneity exists 
which has implications for treatment decisions. This is a key factor for 
determining the appropriate strategies for initiation and maintenance of 
treatment. The disease state is altered by disease severity, clinical 
manifestations, ANCA specificity and patient factors.  
 
As ANCA vasculitis is a rare and complex condition, the aim of this study was 
to identify novel markers of the disease. This would build on the miR-126 
findings reporting vascular dysfunction and examine the miRNome as a whole. 
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In doing this, we sought to determine a novel miR biomarker at disease 
initiation as well as using the marker to track improvement with therapeutic 
interventions. In addition, this biomarker could be used to monitor the patients 
in order to identify those at risk of disease relapse. 
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Aims and hypothesis 
The hypothesis for this study was that, when patients with active disease are 
compared to when they are in remission, differentially expressed miRs will be 





The study was approved by the local research ethics committee and performed 
in accordance with the Declaration of Helsinki. Informed consent was obtained 
from all participants.  For this study, 15 patients with AAV were recruited for 
paired small RNAseq analysis. Patients were recruited from the Vasculitis 
Service at the Royal Infirmary of Edinburgh, UK. Patients who presented with 
sero-positivity for ANCA vasculitis were included. Plasma samples were used 
from patients at entry into the study and at a subsequent follow up visit when 
the condition was considered to be at the remission stage, as defined by the 
BVAS scale, after successful treatment.  
 
Samples were taken and stored immediately at -80oC after being spun in a 
workbench centrifuge at 1,100 x g for 10 minutes at 4oC. Clinical data were 
obtained by clinical staff at the Edinburgh Renal Unit at the Royal Infirmary, 
Edinburgh.  
 
Power of RNAseq study 
ANCA vasculitis is a clinically complex disease with a spectrum of disease 
severity and tissues targeted by inflammatory cells. This study aimed to 
determine a biomarker of disease remission. Initially, a power calculation was 
performed to determine the number of paired samples required for the study 
(Figure 22). We used our existing small RNA sequencing data from human 
serum to model the sample size effect on the ability to obtain 80% power 
corrected for false discovery.149 Across a range of sample sizes there was an 




Figure 22. Small RNAseq power calculations to achieve 80% power.  
The plot shows the proportion of genes ≥80% power versus n per group. 
 
Sample sequencing 
Small RNA sequencing was performed by BGI Genomics (Hong Kong) using 
the BGISEQ-500 system.  Small RNA encompasses all RNA molecules that 
are less than 200 nucleotides long. The system used captured small RNA and 
miR species from the plasma samples. Using the BGISEQ-500 platform, at 
least 20 million clean reads per sample were generated. Samples were 
sequenced to produce 50 base pair long sequences. They were then 
processed initially by BGI to remove the primer sequences. To produce 
sufficiently large datasets, some of the patient samples required multiple 
sequencing attempts.  
 
RNA sequencing analysis 
Initial RNAseq analysis was performed by Dr Al Ivens. The raw sequences 
were pre-processed and assessed for quality using FASTQC to ensure that 
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there were not any recognised primers present. The sequences were then 
aligned to version hg19 of the Homo sapiens genome (obtained from 
Ensembl). Only FLPM alignments to the reference genome were assessed for 
the initial analysis. Alignments to the reference genome were performed using 
bowtie (version 0.12.5) and miRDeep2 (version 2.0.0.4) software. FLPM 
sequences were used for miRDeep2 analysis. Raw aligning sequences were 
obtained for 1335 different mature miRs. The raw counts data were then 
filtered to include only sequences with an average of ≥ 5 reads (836 loci).  
 
Pairwise comparisons of pre-treatment and post-treatment was performed on 
the normalised tag counts using linear modelling and differences were 
identified as the fold change in the group comparison. Significance values 
were controlled for false discovery, yielding a more rigorous adjusted P value.  
 
PCR validation of sequencing results 
Total RNA was extracted from 50l of each patient sample using the 
miRNeasy Serum/Plasma kit (Qiagen) according to the manufacturer’s 
instructions and detailed in Chapter 2.  
 
The RNA from patient samples was then used to generate cDNA with the 
miScript II Reverse Transcription kit (Qiagen) according to the manufacturer’s 
instructions and detailed in Chapter 2. 
 
Real-time quantification was performed using the SYBR green miRNA kit 
(Qiagen) using a Lightcycler 480 machine (Roche). Details of the pre-designed 













Hs_miR-4732-5p_1 hsa-miR-4732-5p MS00037506 5'UGUAGAGCAGGGAGCAGGAAGCU 
Hs_miR-181c*_1 hsa-miR-181c-3p MS00008848 5'AACCAUCGACCGUUGAGUGGAC 
Hs_miR-3150_1 hsa-miR-3150a-3p MS00020678 5'CUGGGGAGAUCCUCGAGGUUGG 
Hs_miR-375_2 hsa-miR-375 MS00031829 5'UUUGUUCGUUCGGCUCGCGUGA 
Hs_miR-483-5p_1 hsa-miR-483-5p MS00009758 5'AAGACGGGAGGAAAGAAGGGAG 
Hs_miR-3192_2 hsa-miR-3192-5p MS00041895 5'UCUGGGAGGUUGUAGCAGUGGAA 
Hs_let-7b_1 hsa-let-7b-5p MS00003122 5'UGAGGUAGUAGGUUGUGUGGUU 




For this study, male and female patients were recruited at disease presentation 
with AAV and subsequently followed up (n = 15 paired). The patients selected 
were confirmed to have AAV, well-defined renal involvement and an adequate 
volume of plasma for sequencing. Plasma samples were sequenced to identify 
small RNAs in active disease and once in treatment-induced remission to 
identify markers of the disease progression and determine the patient’s 
remission status. The patient’s demographic characteristics are shown in 




Table 10. Clinical demographics for vasculitis patients pre- and post-treatment that were included in RNAseq analysis.  
The data are shown as mean ± SD with range. Significance of numerical data between groups was ascertained using a 2-tailed paired t-test.
Characteristics Pre-treatment (n = 15) Post-treatment (n = 15) P value 
Age, years 67 ± 10 (53 - 81) - - 
Sex, M/F 8/7 - - 
Organs involved 3 ± 1 (1 - 6) - - 
- Kidney 15 - - 
- Lung 11 - - 
- ENT 6 - - 
- Nerve 4 - - 
- Eyes 5 - - 
eGFR, mL/min/1.73m2 31 ± 22 (8 - 92) 44 ± 23 (22 - 108) <0.0001 
Serum creatinine, mol/L 233 ± 141 (81 - 605) 146 ± 55 (70 - 257) 0.002 
ALT, U/L 24 ± 22 (6 - 83) 17 ± 7 (5 - 32) 0.25 
ALP, U/L 127 ± 77 (52 - 338) 66 ± 15 (39 - 103) 0.007 
GGT, U/L 67 ± 60 (14 - 182) 21 ± 5 (11 - 28) 0.02 
Albumin, g/L 25 ± 7 (17 - 39) 36 ± 4 (27 - 41) <0.0001 
CRP, mg/L 114 ± 86 (11 - 275) 4 ± 4 (0 - 12) 0.0002 
Haemoglobin, g/L 90 ± 18 (62 - 125) 123 ± 11 (99 - 143) <0.0001 
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RNAseq quality control  
Quality control was conducted on the 15 paired samples following small RNA 
sequencing. Figure 23 shows the boxplots for the 836 miRs with ≥ 5 reads in 
each sample. This illustrates all samples scaled down to have an identical 
number of reads aligning to miRs. It also shows the quantile normalised for the 
samples to normalise the distributions between patient samples. Due to 
abnormal boxplot distributions, five paired samples were removed from further 
analyses, resulting in ten paired patient samples. As this study was designed 
as paired analysis, if either the pre- or post-treatment sample distribution was 
abnormal, both samples were removed from further analysis. This allowed the 
group membership balance to be maintained for group wise interpretation. The 

















Figure 23. Quantile normalised boxplots for the 836 miRs with an average of ≥ 5 reads.  





























































































































































































































































































































































































































































































































































































































































Analysis of individual comparisons by RNAseq 
Following quality control for the patient samples, further analysis was 
conducted to determine the degree of relatedness for the remaining paired 
samples (n = 10 paired). To do this, principal component analysis (PCA) was 
performed (Figure 24). This demonstrated that there was low level of similarity 
between the cohorts. The individual patient samples for pre- and post-
treatment were more closely related overall, which suggested that it would be 
more appropriate to measure miR expression in individual samples, rather 
than treatment cohorts.  
 
Further analysis of the individual patient’s miR expression was conducted. A 
heatmap was produced to illustrate the miR expression hits for post- relative 
to pre-treatment (Figure 25). The analysis from the 10 paired patient samples 
showed that there were not any significantly differentially expressed mature 
miR markers of vascular health and disease in this cohort. There was a high 
level of variation within the sequenced group and this was illustrated in the 






Figure 24. Principal component analysis of the relatedness of the pre and post-treatment samples from RNAseq.  
The axes represent the genetic variability of the samples which were sequenced.  Pre-treatment samples are shown in red and post-treatment are shown in blue.  The 
axes represent the degree of variability between samples. 
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Figure 25. Differential expression changes post-treatment relative to pre.  
The x-axis represents the 836 mature miRs identified with RNAseq and the y-axis represents the paired cohort comparison between the treatment groups for each 
individual patient. 
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Summary of raw data 
In total, 836 mature miRs were identified in the pre- and post-treatment paired 
samples.  Circulating miRs post- relative to pre-treatment were analysed for 
variation in their fold change between the two disease states (Figure 26). For 
the fold change profile, without statistically filtering the data, 453 miRs were 
upregulated post-treatment and 383 miRs were downregulated. For >2-fold 
change, 129 miRs were upregulated and 124 were downregulated. 
 
 
Figure 26. Volcano plot of group comparisons post-treatment relative to pre-treatment.  
The plot shows -log(10) raw P value versus log2 fold change for the group comparison. Red lines 
transecting the x- and y- axis demonstrate ± 1-fold change and P-value 0.05 respectively. The red dot 
illustrates the expression of miR-126 in this analysis. 
 
The 9 miRs exhibiting the largest differential expression changes between the 
two groups are shown in Table 11. The 9 mature miRs were statistically 
significant (5 up-regulated and 4 down-regulated). Within the significant 
features, hsa-let-7b, hsa-mir-3150a, hsa-mir-3192, hsa-mir-375 and hsa-mir-
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4732 were up- regulated. Within the significant features, hsa-mir-181c, hsa-
mir-365a and hsa-mir-483 were down-regulated. 
 
Mature miR Log fold change Raw P value Average expression 
hsa-let-7b-5p 1.0 0.05 22 
hsa-miR-181c-3p -3.2 0.03 4.8 
hsa-miR-3150a-3p 4.1 0.03 3.7 
hsa-miR-3192-5p 2.3 0.04 1.6 
hsa-miR-365a-3p -2.5 0.05 2.9 
hsa-miR-365b-3p -2.5 0.05 2.9 
hsa-miR-375 1.5 0.03 16 
hsa-miR-4732-5p 2.0 0.002 11 
hsa-miR-483-5p -2.6 0.04 13 
Table 11. Circulating miRs exhibiting the largest differential expression (fold change) in the post- 
relative to pre-treatment groups.  
The average expression is the average log2 signal intensity of the probe set across all arrays, as a 
method to normalise the data. 
 
The 9 miRs of interest were further analysed to assess their differential 
expression in patients pre- and post-treatment. Figure 27 demonstrates the 
expression patterns between the treatment groups. In addition, the heatmap 
illustrates the variation within the treatment groups. The 9 miRs were, has-let-
7b-5p, hsa-miR-181c-3p, hsa-miR-3150a-3p, hsa-miR-3192-5p, hsa-miR-































Figure 27. Heatmap for the differential expression changes of miRs of interest.  











































































































Validation of RNAseq hits by qRT-PCR 
The process of miR validation was performed using qRT-PCR. Samples were 
collected and processed following the conditions described above. The same 
10 patient’s samples (from pre- and post-treatment) were used to validate the 
miRs of interest from the RNAseq analysis. Further analysis was not carried 
out on miR-365b-3p as it was a replicate of miR-365a-3p. The qRT-PCR 
validation was performed and analysed using raw Ct expression (Figure 28) 
and relative expression using the 2-Ct method using C. elegans miR-39 as an 
exogenous normaliser for miR expression (Figure 29). Neither raw Ct nor 
relative expression demonstrated the differences between the treatment 
groups observed with RNAseq. There was not a significant difference for pre- 
and post-treatment for any of the validated miRs of interest using qRT-PCR, 
therefore the miRs of interest in the patient samples could not be validated 
using this method. The primer sequences were validated between qRT-PCR 
and RNAseq to ensure that there were no discrepancies which would produce 




Figure 28. Plasma qRT-PCR validation of miR expression changes.  
The change in miR expression was measured in a panel of miRs, identified as hits in RNAseq. The miRs 
measured pre- and post-treatment were (A) let-7b-5p, (B) miR-181c-3p, (C) miR-3150a-3p, (D) miR-
3192-5p, (E) miR-365a-3p, (F) miR-375, (G) miR-4732-5p and (H) miR-483-5p. Significance was 
determined using a Wilcoxon test for paired analysis.  
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Figure 29. Relative quantification for plasma qRT-PCR validation of miR expression changes.  
The change in miR expression was measured in a panel of miRs, identified as hits in RNAseq. The miRs 
measured pre- and post-treatment were (A) let-7b-5p, (B) miR-181c-3p, (C) miR-3150a-3p, (D) miR-
3192-5p, (E) miR-365a-3p, (F) miR-375, (G) miR-4732-5p and (H) miR-483-5p. Data are expressed as 




Discovering novel biomarkers for health and disease is essential for the 
development of medical therapeutics and disease diagnosis.75 The main 
objective of this study was to determine a panel of miR biomarkers to 
differentiate between active ANCA vasculitis and once treatment-induced 
remission has been achieved. Using paired patient samples at both stages of 
the disease, small RNA sequencing identified 9 differentially expressed miRs 
in the patient samples. These hits were explored with qRT-PCR, which did not 
align with the expression differences. Analysis of variance between the sample 
groups demonstrated that there was a high degree of heterogeneity in the 
patient groups.  
 
Small RNAseq identifies differential expression in vasculitis  
BGISEQ-500 is a novel platform for next generation sequencing (NGS) for 
large scale DNA and RNA sequencing.150, 151 It has been previously validated 
in small RNAs and shows high technical reproducibility.152 Using this 
technology, 9 hits were identified as miRs which were differentially expressed 
between pre- and post-treatment vasculitis in whole patient cohorts. The 9 hits 
chosen were significantly different between the two groups and therefore 
appropriate to assess for biomarker discovery. After further analysis, miR-
375b-3p was discovered to be a replicate of miR-375a-3p and therefore 
removed from further validation. The data were also assessed as individual 
patient’s pre- versus post-treatment to determine whether differences existed 
for each patient at the two disease states, which would allow for a greater 
understanding of the various forms of the disease. By interpreting the data in 
this way, there were not any significantly differentially expressed miRs for the 
two disease groups. This suggested that there were not any suitable miR 
biomarkers to differentiate between active disease and treatment induced 
remission in the small cohort of ANCA vasculitis patients that were recruited. 
Notably, miR-126 was not differentially expressed in the RNAseq analysis. 
This implies that the RNAseq had some limitations and did not identify all of 
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the potential microRNA expression differences between the two patient 




In order to develop a biomarker of disease, validation of RNAseq hits is 
required.153 For miRs, a widely used and robust method of validation is qRT-
PCR. RNAseq data for fold-changes in expression correlate with qRT-PCR 
expression.154 This study did not show this relationship. The miR hits for 
differential expression between the treatment groups were not confirmed by 
qRT-PCR. The primer sequences were validated between the two 
technologies and there were no discrepancies detected. Due to this, it was not 
possible to further validate the hits. This is potentially explained by the 
differences in sensitivity between RNAseq and qRT-PCR. Further 
development of this relationship is required in larger patient cohorts. An 
additional explanation is that the miRs of interest were expressed at a low level 
in the RNAseq and this was reflected in the high Ct values with qRT-PCR. This 
could suggest that the miRs may have been undetectable with qRT-PCR.  
 
Heterogeneity of ANCA vasculitis 
As ANCA vasculitis represents a spectrum of disorders, including GPA, MPA 
and EGPA, there is an array of clinical manifestations.155 In addition, the 
underlying immune dysfunction can lead to a variety of tissues being 
targeted.156 In turn, the patient presents with symptoms representing their 
organ involvement, often including more than one. This is a fundamental issue 
in defining an appropriate biomarker for ANCA vasculitis.43 In addition, there 
is a variable disease course which may be mild or systemic and life 
threatening. Due to this, there are challenges in defining an appropriate marker 
to comprehensively diagnose and track ANCA vasculitis. This is demonstrated 
in the complex heterogenous data obtained in this study.  
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Small RNAseq biases 
There are a multitude of known small RNAseq biases which may affect the 
interpretation of the data and makes reliable quantification complicated. One 
of the challenges for quantifying miRs is the presence of isoforms, known as 
isomiRs, which are produced during biogenesis. The isomiRs show variations 
in stability, localisation, and functionality. The slight differences in length at the 
5′ termini, 3′ termini, or both, creates difficulties for small RNAseq and 
validation with qRT-PCR.157 Other important biases result from the RNAseq 
library preparation. These are based on inconsistencies associated with 
adapter ligation, cDNA synthesis, and amplification and are fundamentally 
dependent on library preparation and pre-processing methods, which are not 
as well controlled.158 These biases may have had a crucial impact on the 
results obtained for the study. Further analysis and comparison on the small 
RNAseq would be required if the study were to be repeated. 
 
Limitations 
The study would have been more powerful if more paired samples had 
undergone RNAseq analysis. Due to resource limitations, it was not possible 
to sequence as many samples as would be ideal. The power calculation was 
performed based on data previously obtained by the group in patients with 
myocardial injury. As this cohort is considerably different clinically, this was 
potentially a limitation to the power of the study. In addition, due to abnormal 
boxplot distributions for 5 patients, the number included in the study was 
reduced from 15 to 10. This had a significant impact on the power of the study 
and was suboptimal for a human cohort.  
 
To improve the overall design of this study, it would also have been of interest 
to include health age and sex-matched volunteers for comparison. This would 
have allowed for a greater understanding of the miRNome differences between 
systemic vascular inflammation and health individuals. As ANCA vasculitis is 
an extreme phenotype, it would have been possible to define miRs in active 
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disease and health, as shown in Chapter 3 with miR-126. With additional time 
and resources, this would be a valuable study to conduct. Overall, defining a 
suitable novel miR biomarker of ANCA vasculitis had multiple challenges, 






In this study the circulating miR profile did not change in human subjects 
between active vasculitis (pre-treatment) and in remission (post-treatment). 
There is potential for novel miR biomarker discovery, however, these were not 
detected with the platform used. This is potentially a consequence of vasculitis 
being a very heterogeneous disease with varying target organs and degrees 




Chapter 6 – Extracellular vesicle 






In AAV, patients suffer from chronic inflammation. This is a major contributor 
in the development of cardiovascular disease, including ischemic heart 
disease, cerebrovascular events, thromboembolisms159 and peripheral arterial 
disease.160 In addition, patients are at increased risk of developing chronic 
kidney disease.22 AAV is characterised by necrotising vasculitis with neutrophil 
and monocyte infiltration, resulting in vessel injury.15 The inflammatory cells 
are recruited to the site of the vascular damage by cytokines. Pro-inflammatory 
cytokines are fundamental for cell to cell communication161 and damage the 
vasculature and cause inflammation in the vessel wall.162 They are major 
producers and up-regulators of inflammatory reactions. This is a key 
component of the pathogenesis of vasculitis and systemic inflammation.163 
Macrophages are tissue-resident phagocytic cells that are fundamental for 
host defence from infection. Immune cells are present throughout the body in 
all organs, where they identify and remove debris and foreign matter. 
Macrophages are responsible for regulating the inflammatory response as well 
as tissue repair.  
 
Previous studies have shown that ECVs can directly mediate immune cell 
responses. This is due to their ability to transport miRs, proteins and other 
components to facilitate cell to cell communication.164 This means that ECVs 
can be released from a damaged cell and affect the physiology of neighbouring 
recipient cells. This is can be the result of the ECVs inducing intracellular 
signalling after binding to cell receptors or presenting new properties after 
gaining new receptors, enzymes or genetic material.165  Immune cell ECVs 
have been shown to regulate the vascular endothelium. The vascular 
inflammatory status can determine the secreted ECVs and therefore facilitate 
ECVs derived from the endothelium to differentially modulate target cell 
responses. This process has been demonstrated for both a pro- and anti-
inflammatory response.166 In the kidney, ECVs are released into urine from all 
regions of the nephron.167 They have been implicated in the pathogenesis of 
acute kidney injury by transferring TGF-β1 mRNA into fibroblasts which 
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resulted in cell activation.168 This makes them an interesting area of research 
to determine their role in immune and renal cells during active AAV. 
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Aims and hypothesis 
The hypothesis for this chapter is that in ANCA vasculitis, circulating ECVs 
directly mediate pathophysiological changes in the vasculature, inflammatory 
cells and in the kidney. ECVs isolated from patients with vasculitis, before and 
after treatment, will play differing functional roles when applied to 
macrophages in vitro, by activating a defined inflammatory response. In 
addition, ECVs will cause cell damage in renal proximal tubules in vitro. This 
study aimed to determine the effect of ECVs from patients with ANCA 
vasculitis on murine macrophages, human macrophages and renal tubular 








Vesicles were obtained from plasma taken from healthy volunteers and 
vasculitis patients at disease presentation and once in disease remission after 
successful therapeutic treatment, as described in Chapter 3. ECVs from 
human blood plasma were isolated following the Thery et al. protocol for 
purification of ECVs from viscous fluids.169 Briefly, the plasma was diluted with 
an equal volume of PBS before undergoing 30 minutes of centrifugation at 
2,000 x g at 4oC to pellet dead cells. The supernatant was removed and added 
to ultracentrifuge tubes and centrifuged at 12,000 x g for 45 minutes at 4oC to 
pellet the cell debris. The supernatant was transferred to new ultracentrifuge 
tubes and centrifuged for 2 hours at 110,000 x g. The pellet was resuspended 
in 1mL of PBS before being diluted to obtain 4mL of resuspension. This was 
filtered through a 0.22μm filter (Merck Millipore, Livingston, United Kingdom). 
The filtered solution was centrifuged at 110,000 x g for 1 hour and 10 minutes 
at 4oC. The pellet was resuspended in PBS and again centrifuged at 110,000 
x g for 1 hour and 10 minutes at 4oC. The supernatant was poured off and the 
pelleted ECVs (including exosomes) were resuspended to give a final 
suspension in PBS.  
 
ECV quantification 
ECVs were sized and quantified with NTA using the NanoSight LM 10 
instrument (NanoSight Ltd, Amesbury, United Kingdom). The equipment 
visualises particles in liquids (10 to 1000 nm) and relates the rate of Brownian 
motion to particle size. The system settings were optimised and kept constant 
for all samples. Each video record was analysed to give the mean, mode, 
median and estimated concentration for each particle size. All sample analysis 
was carried out at a 1:1000 dilution of the sample in distilled water in 
accordance with the manufacturer’s guidance. Measurements were in 
triplicate. Measurements were plotted and the AUC calculated for ECVs of 
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exosomal size (20 - 100 nm) to determine the concentration of vesicles in each 
sample. After isolation, samples were stored at -20oC until required. 
 
ECV fluorescent labelling 
The pelleted ECVs were labelled with Cell Tracker 655 (Invitrogen, Paisley, 
United Kingdom) following the manufacturer’s protocol. The ECVs were 
incubated with Qtracker 655 Cell Labelling dye (Invitrogen) in media without 
FBS, to avoid the addition of vesicles from the serum, for 45 minutes at 37oC 
before removing excess dye with two PBS washes and centrifugation at 
110,000 x g for 1 hour and 10 minutes. A separate stock of unlabelled vesicles 
was stored for use in experiments which did not require fluorescently labelled 
ECVs, including qPCR.  
 
Bone marrow-derived macrophages from mice  
Bone marrow-derived macrophages (BMDMΦ) were derived from the femur 
and tibia of C57BL/6, male or female, 6-12 weeks old mice. The mice were 
culled by schedule 1 killing and de-trousered before being washed with 70% 
ethanol to limit contamination of the sample with fur and dander. The femur 
was exposed by cutting through the rectus femoris and biceps femoris muscles 
that surround the bone. All tissue was removed from the bones to enable 
detachment of the hip and knee joint from the femur and tibia. The epiphysis 
of the femur and tibia were removed using bone cutters and a syringe 
containing media (DMEM/F12 media with added FBS (10%), L929 (20%), 
penicillin and streptomycin (Gibco, Paisley, United Kingdom), with a 251/2 
gauge needle, was inserted into the diaphysis of the bone and flushed through. 
The bone marrow was then suspended in media and incubated at 37oC with 
5% carbon dioxide. 
  
Following bone marrow extraction from the mouse, the primary cells were 
grown over 8 days to differentiate into BMDMΦ cells. They were passaged 




per mL in 12 well tissue culture-treated plates to allow for adhesion of 
the cells to the wells for 24 hours. Cells were washed with PBS warmed to 
37oC to remove the remaining FBS before co-culturing with ECVs. 
 
Vesicles isolated from human plasma were added at 1x109
 
per mL. For cells 
used in qPCR and ELISA, ECVs were left unstained. For immunofluorescent 
imaging and flow cytometry, vesicles were stained with Qtracker 655 Cell 
Labelling dye as detailed above. ECVs were diluted to 1x109
 
per mL in media 
without the addition of FBS and incubated at 37oC and 5% CO2 for 0 to 18 
hours. The duration of serum starvation was kept constant throughout the 
study for all groups.  
 
Flow cytometry  
Cell fluorescence was measured by flow cytometry using a 5LSR Fortessa 
cytometer (BD Biosciences, Oxford, United Kingdom). BMDMΦ cells were 
exposed to dye loaded ECVs, as described, before detachment using a cell 
scrape with PBS. Detached cells were transferred to FACS tubes before being 
centrifuged at 300 x g for 5 minutes at 4oC. The supernatant was removed 
before blocking with 10% mouse serum for 20 minutes on ice. The cells were 
incubated for a further 30 minutes with 1:2000 dilution of FITC anti-
mouse/human CD11b antibody (Cat number: 101206, Biolegend, London, 
United Kingdom) in darkness. PBS was added after the incubation and 
centrifuged at 300 x g for 5 minutes at 4oC. The supernatant was removed and 
200μl formalin added. Samples were stored in darkness at 4oC and analysed 
within 2 hours. FACS was run using an optimised protocol for QDots with 
excitation at 655nm and FITC at 488nm. For all samples, 10,000 events were 
used as the threshold value. Unstained and single stained samples were used 
for controls for use in analysis with FlowJo software. The gating strategy used 
for flow cytometry was optimised by Dr Wilna Oosthuyzen and Dr Emma 
Morrison previously. Gates were set using unstained cells and cells stained 
with DAPI alone. The populations of interest were identified using the 
FSC/SSC parameter. FITC positive single cells were measured and those 
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containing QDot 655nm labelled vesicles. The results are presented as the 
percentage of total fluorescent cells.  
  
Immunofluorescence  
Cultured cells were dispensed into separate clear 12 well plates with coverslips 
placed at the bottom of each well to facilitate growth. Initially, wells were 
washed twice with PBS to remove media and fixed with 4% paraformaldehyde 
(PFA) for 15 minutes. The wells were washed twice with PBS and 0.3% triton 
added to permeabilize the membranes. Wells were again washed after 10 
minutes with PBS (twice). Cell filamentous actin was stained using Alexa Fluor 
488 Phalloidin antibody (Cat number: A12379, Molecular Probes, Paisley, 
United Kingdom). The antibody was added at 1:500 dilution at room 
temperature in darkness. The samples were washed with PBS before 
mounting with DAPI, Fluoromount-G (SouthernBiotech, Cambridge, United 
Kingdom). Once dried, the slides were stored in darkness at 4oC until imaging.  
 
Image capture and analysis  
Images were captured using a confocal laser scanning microscope (LSM 710, 
Zeiss, Cambridge, United Kingdom). Exposure, brightness and magnification 
were optimised and kept constant for all slides. Images were collected with a 
64x oil immersion objective lens and acquired using ZenPro Software (Zeiss).  
Image analysis was performed using ImageJ software.  
 
RNA extraction  
Total RNA was extracted following the manufacturer’s protocol using the 
RNeasy Mini Kit (Qiagen, Venlo, Netherlands). RNA concentration was 
measured using a Nanodrop. Samples were diluted to give a consistent RNA 
concentration and stored at -80oC. 
 
 131 
Reverse Transcription PCR  
Following extraction, each elute of RNA was reverse transcribed into cDNA 
with miScript II RT Kit (Qiagen) according to the manufacturer’s instructions. 
 
Quantitative PCR  
A standard curve was created for quantification of gene expression. The qPCR 
was performed using SYBR Green (Qiagen) with murine primers (listed in 
Table 12) or human specific QuantiTect Primer assays (Qiagen). The plate 
was centrifuged at 2000 x g for 2 minutes at room temperature to collect all 
liquid in the bottom of the wells to remove experimental variation. The qPCR 
was carried out on a Lightcycler480 (Roche). Dissociation curves were utilised 
to ensure the amplification of a single product.  
 
Primer Sequence 
Gapdh - Forward  ACT GGC ATG GCC TTC CG 
Gapdh - Reverse  CAG GCG GCA CGT CAG ATC 
Arg1 - Forward  GTG GAT GCT CAC ACT GAC ATC A  
Arg1 - Reverse  GGT TGC CCA TGC AGA TTC C 
Il1b - Forward  AGT TGA CGG ACC CCA AAA GAT  
Il1b - Reverse  GGA CAG CCC AGG TCA AAG G 
Il6 - Forward CCA CGG CCT TCC CTA CTT 
Il6 - Reverse  TTG GGA GTG GTA TCC TCT GTG A  
Il10 - Forward  CCC AGA AAT CAA GGA GCA TTT G  
Il10 - Reverse  CGC ATC CTG AGG GTC TTC A 
Mrc1- Forward  TCA TTG GAA CAT CCA CTC TGG  
Mrc1- Reverse  CAG CGC TTG TGA TCT TCA TTA TAG  
Tnfa - Forward  CAC AAG ATG CTG GGA CAG TCA  
Tnfa - Reverse  TCC TTG ATC GTG GTG CAT GA  
Table 12. Primers used for qPCR for murine inflammatory genes. 




Human macrophage isolation 
Human peripheral blood monocytes were isolated from healthy human blood 
by dextran sedimentation followed by percoll gradient centrifugation. 
Monocytes were seeded onto glass coverslips in 12 well plates at 2x106 cell 
per mL in serum-free Iscove’s modified dulbecco’s medium (IMDM; Gibco). 
After 1 hour, cells were washed to remove non-adherent cells. Adherent cells 
were cultured for 7 days in IMDM with 10% donor serum. After this time, cells 
were co-cultured with ECVs as detailed above.  
 
RPTEC/TERT1 cells 
REPTEC/TERT1 cells are commercially available epithelial cells immortalised 
with pLXSN-hTERT retroviral transfection. Cells were grown in DMEM:F12 
media (ATCC, Middlesex, United Kingdom) in 75cm2 flasks. Once confluent, 
cells were seeded into 12 well plates at 1.5x105 cells per mL and left for 72 
hours to adhere. Cells were incubated with isolated ECVs following the 
protocol detailed above.   
 
Statistical analysis  
All analysis was performed using GraphPad Prism software (GraphPad, La 
Jolla, United States). Statistical significance was calculated using a one-way 
analysis of variance (ANOVA) with Bonferroni’s multiple comparison post-test 
for comparison to healthy controls and for all FLOW analysis. For pre- and 




Human ECV uptake by murine bone marrow-derived macrophages 
After ECV isolation by differential ultracentrifugation, NTA was used to 
measure the concentration of ECVs isolated from human plasma samples from 
healthy volunteers. A representative trace obtained from the NTA analysis is 
presented in Figure 30A, showing the particle size concentration distribution. 
ECVs isolated from healthy volunteers were fluorescently labelled using Cell 
Tracker 655 then added to BMDMΦ for various incubation periods to 
determine the optimal time required for uptake. Figure 30B demonstrates the 
number of CD11b positively stained macrophages, as determined by the pan-
macrophage marker170. There was no significant difference in positively 
marked macrophage single cells at the measured time points between 0 and 
18 hours. Figure 30C displays the number of single cells with successful 
uptake of ECVs. In Figure 30D, CD11b positive cells took up QDot tracker 
labelled ECVs in a time-dependant manner with a maximum level of uptake 
after 18 hours of co-culturing.  
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Figure 30. ECVs isolated from human plasma can be taken up by BMDMΦ in a time-dependant manner.  
(A) Representative NTA trace of ECVs isolated from plasma. The line represents the threshold between ECVs considered to be of exosomal size. Flow cytometry was 
used to quantify the uptake of ECVs into recipient CD11b cells (B) Quantification of CD11b cells in BMDMΦ cell culture. (C) Single cells taking up Qdot tracker labelled 
ECVs and (D) the percentage CD11b positive single cells with QDot tracker labelled ECVs at varying time points ranging from 0 to 18 hours. Bars show mean with SD 
(n=3 per group with 10,000 events each) *p<0.05 ***p<0.001, ****p<0.0001 (One-way ANOVA with Bonferroni’s multiple comparisons test). 
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In order to visualise the capabilities of BMDMΦ cells to take-up ECVs isolated 
from human plasma, ECVs from healthy volunteers were labelled and added 
to cells for 18 hours before fluorescent imaging. The images obtained, shown 
in Figure 31, are representative of the control cells (incubated without the 
addition of labelled ECVs) and with the ECVs from healthy volunteers and 
patients with active vasculitis, pre-treatment. This demonstrated that labelled 
ECVs can successfully be taken up by the BMDMΦ after 18 hours of 
incubation. The ECVs can be seen intracellularly near the nuclei. This is also 
seen in the cells co-cultured with the vasculitis patient’s ECVs.  
 
 
Figure 31. Cultured murine BMDMΦ take up labelled ECVs isolated from human plasma.  
Representative images using fluorescent microscopy of BMDMΦ cells (A) cultured without ECVs, (B) 
BMDMΦ cells with fluorescently loaded ECVs from healthy volunteers and (C) xwith ECVs isolate from 
patients with active vasculitis. The images show ECVs (red), nuclei stained with DAPI (blue) and cell 
membrane stained with phalloidin (green). Images are representative of 3 samples for each group. Scale 
bars are 20µm. 
 
Human ECVs alter murine macrophage phenotype  
ECVs isolated from plasma taken from patients with vasculitis, pre- and post-
treatment, were quantified by NTA and the number of ECVs normalised for 
each individual. ECVs were added to BMDMΦ cells and co-cultured for 18 
hours, as determined by flow cytometry. The cellular gene expression - for 
multiple inflammatory markers - was measured in the macrophages. The 
relative change in expression for five genes is presented in Figure 3 and 4. 
The genes were measured in order to ascertain the potential pro- or anti-
inflammatory response in the cells after co-culturing. For the classic 
macrophage response, the cytokines tested were Tnfa and Il1b (Figure 32). 
There was not a significant increase in gene expression for either cytokine. 
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Figure 33 demonstrates the gene expression of cytokines involved in the 
alternative macrophage response, considered to be anti-inflammatory. Mrc1 
shows an increase in gene expression in macrophages with ECVs from pre- 
and post-treatment. There was no significant difference in expression for Il10 
and Arg1 between ECVs from patients with vasculitis and healthy controls.  
 
 
Figure 32. Gene expression to measure the pro-inflammatory response in BMDMΦ cells after ECV 
uptake.  
The fold change of cytokines was measured. The cytokines are involved in the M1 inflammatory 
response including (A) Il1b and (B) Tnfa. Each point represents the 2-ΔΔCT value, normalised to GAPDH 
and untreated control cells. The dotted line represents no change in expression in comparison to 
untreated control cells. Bars show mean with SD (n = 10 per group in triplicate, one-way ANOVA with 
Bonferroni’s multiple comparisons test). 
 137 
 
Figure 33. Gene expression to measure the anti-inflammatory response in BMDMΦ cells after 
ECV uptake.  
The fold change of cytokines was measured. The cytokines are involved in the M2 inflammatory 
response including (A) Arg1, (B) Il10 and (C) Mrc1. Each point represents the 2-ΔΔCT value, normalised 
to GAPDH and untreated control cells. The dotted line represents no change in expression in comparison 
to untreated control cells. Bars show mean with SD (n=10 per group in triplicate) *p<0.05 (one-way 
ANOVA with Bonferroni’s multiple comparisons test). 
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Human ECVs are taken-up by human primary macrophages 
Human peripheral blood mononuclear cells (PBMCs) were isolated and 
cultured from healthy volunteers to assess the capabilities of human 
macrophages to take-up ECVs isolated from human plasma. ECVs from 
healthy volunteers were labelled and added to cells before fluorescent 
imaging. The images obtained, shown in Figure 34, are representative of the 
control cells (incubated without the addition of labelled ECVs) and with the 
ECVs after co-incubation for 24 hours and 48 hours. Figure 34B demonstrates 
that labelled ECVs can successfully be taken up by the primary human 
macrophages after 24 hours of incubation. There was also uptake of the 
labelled ECVs at 48 hours (Figure 34C), however, the level of uptake was 
consistent with the 24-hour incubation period. The ECVs can be seen 




Figure 34. Human primary macrophages take up human ECVs from healthy volunteers.  
(A) Fluorescent microscopy of human macrophages without ECVs and (B) with fluorescently loaded 
ECVs at 24 hours and (C) 48 hours of co-culturing. Fluorescently loaded ECVs (red), nuclei stained with 
DAPI (blue) and cell membrane was stained with phalloidin (green). Images are representative of 3 
samples for each group.  
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Human macrophages do not have altered phenotypes after ECV uptake 
ECVs were isolated from AASV patient’s plasma pre-treatment in addition to 
healthy volunteers. The ECVs were added to human primary macrophages 
and the gene expression for multiple inflammatory markers were measured. 
The relative change in expression for the six genes measured is presented in 
Figure 35 and Figure 36. The genes tested to measure a classic macrophage 
phenotype were TNFa, IL1b and IL6, shown in Figure 35. There was not a 
significant difference in gene expression between the control cells, cells 
treated with healthy volunteer’s ECVs and ECVs from vasculitis patients with 
active disease. 
 
Cytokines involved in the alternative macrophage phenotype were also 
measured (Figure 36). These were IL10, MRC1 and ARG1. There was no 
detectable change in expression between healthy and AASV samples. These 
data demonstrate that there are no regulatory changes in the healthy and 
diseased state for ECV uptake in macrophages.  
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Figure 35. Gene expression to measure the pro-inflammatory response in human PBMCs after 
ECV uptake.  
The fold change of cytokines was measured. The cytokines are involved in the M1 inflammatory 
response including (A) IL1B (B) IL6 and (C) TNFA. Each point represents the 2-ΔΔCT value, normalised to 
GAPDH and untreated control cells. The dotted line represents no change in expression in comparison 
to untreated control cells. Bars show mean with SD (n = 4 per group in triplicate, one-way ANOVA with 
Bonferroni’s multiple comparisons test). 
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Figure 36. Gene expression to measure the anti-inflammatory response in human PBMCs after 
ECV uptake.  
The fold change of cytokines was measured. The cytokines are involved in the M2 inflammatory 
response including (A) ARG1, (B) IL10 and (C) MRC. Each point represents the 2-ΔΔCT value, normalised 
to GAPDH and untreated control cells. The dotted line represents no change in expression in comparison 
to untreated control cells. Bars show mean with SD (n = 4 per group in triplicate, one-way ANOVA with 
Bonferroni’s multiple comparisons test). 
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RPTEC/TERT1 human proximal tubule cell line uptake of labelled ECVs 
Previous studies have demonstrated that ECV uptake is possible in human 
proximal tubule cells, however uptake has not been compared in ECVs from 
healthy volunteers and those with acute vascular inflammation. The ability of 
the human proximal tubule cell line, RPTEC/TERT-1, to take-up ECVs was 
confirmed by immunofluorescence using ECVs isolated from healthy 
volunteers’ plasma (Figure 37). The labelled ECVs are abundant at 24 and 48 
hours and absent in the control cells (cultured without human ECVs). The 




Figure 37. A human proximal tubule cell line can take up human ECVs.  
Fluorescent microscopy of RPTEC/TERT-1 cells (A) without ECVs and with fluorescently loaded ECVs 
(B) at 24 hours and (C) at 48 hours of co-culturing. Fluorescently labelled ECVs (red), nuclei stained with 
DAPI (blue) and cell membrane was stained with phalloidin (green). Images are representative of 4 
samples for each group. 
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ECVs do not alter a biomarker of renal injury 
A biomarker commonly used to reflect human tubular injury is HAVCR1. 
RPTEC/TERT-1 cells were co-cultured with ECVs from healthy controls and 
patients with active vasculitis. Additionally, the tubular cells were separately 
treated with two concentrations of cisplatin to confirm cell damage (Figure 
38A). Gene expression of HAVCR1 was not altered by the healthy or active 
vasculitis ECVs. The cisplatin treatment resulted in a significant difference in 
HAVCR-1 gene expression between 10M and 100M.   
 
HAVCR1 protein expression within the cell supernatant was quantified 
following RPTEC/TERT-1 co-culturing with ECVs and nephrotoxic cisplatin. 
This was conducted to confirm the injury response at a proteomic level with 
active vasculitis ECVs. The ECVs from patient samples had no substantial 
effect on HAVCR-1 release from cells (Figure 38B). After treatment with 
100M cisplatin, the concentration of HAVCR1 increased in comparison to the 
control cells, including DMSO treated cells, and the tubule cells cultured with 
human ECVs.  
 
Figure 38. HAVCR1 expression in treated RPTEC/TERT-1 cells. 
Renal proximal tubules treated with a nephrotoxin (10M and 100M cisplatin) and ECVs from healthy 
volunteers and patients with active vasculitis. (A) qRT-PCR analysis of HAVCR1 gene expression. Each 
point represents the 2-ΔΔCT value, normalised to GAPDH and untreated control. (B) Protein expression 
in the cell supernatant (n = 3-4 per group in triplicate) *p<0.05, ** p<0.005 (one-way ANOVA with Tukey 
multiple comparison). Horizontal lines represent the mean values and SD. 
 146 
ECVs from AASV patients do not instigate apoptosis 
Apoptosis is often a consequence of renal cell injury from nephrotoxic agents. 
In RPTEC/TERT-1 cells, apoptosis was measured using CASP3 after co-
culturing with cisplatin (10 and 100M) and ECVs isolated from healthy 
controls and patients with active AAV. Figure 39A demonstrates that at 100M, 
cisplatin increases gene expression of CASP3 significantly in comparison to 
other groups tested, including the cells cultured with ECVs from vasculitis 
patients. In addition to CASP3, CSF1 was measured in the RPTEC/TERT-1 
cells (Figure 39B). CSF1 is involved in macrophage recruitment in the proximal 
tubule. There was a significant difference in expression of CSF1 in the cells 
treated with 100M in comparison to the control groups and the cells treated 
with human ECVs.  
 
 
Figure 39. CASP3 and CSF1 gene expression in RPTEC/TERT-1 cells. 
Renal proximal tubules treated with a nephrotoxin (10M and 100M cisplatin) and ECVs from healthy 
volunteers and patients with active vasculitis. Gene expression was measured by qRT-PCR analysis of 
(A) CASP3 and (B) CSF1. Each point represents the 2-ΔΔCT value, normalised to GAPDH and untreated 
control supernatant (n=3 per group in triplicate. ***p<0.001, ****p<0.0001 (one-way ANOVA with Tukey 
multiple comparison). Horizontal lines represent the mean values and SD. 
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Discussion 
The role of ECVs in cardiovascular disease and inflammation is an emerging 
area of research, primarily due to their potential use in biomarker discovery for 
a multitude of cardiovascular diseases.171, 172 The role of ECVs is to transport 
miRs, protein and RNA between cells, resulting in an altered phenotype for the 
recipient cell. The key mechanisms involved in this process have yet to be fully 
investigated.173, 174 Research is ongoing to discover the processes involved in 
ECV development, cargo organisation and the release of vesicles. The 
hypothesis for this chapter was that in ANCA vasculitis, circulating ECVs 
contain a pathognomonic cargo of miRs. These vesicles directly mediate 
pathophysiological changes in the vasculature, inflammatory cells and in the 
kidney.  
 
This study was conducted to determine whether vesicles could be taken up by 
inflammatory and renal cells. The primary aim of this was to determine the 
biodistribution of the vesicles in macrophages, as shown by BMDMΦs and 
PBMCs, and in the kidney, as shown in RPTECs. In this study, the data 
obtained established that human ECV uptake is possible in recipient primary 
murine macrophages as well as primary human macrophages. We have also 
demonstrated that this uptake is possible in a human proximal tubule cell line. 
Our data have established that a change in gene expression is induced by 
ECVs in murine macrophages but not in human macrophages or tubular cells.  
 
Vesicle uptake in vitro  
The first aim of this chapter was to establish whether macrophages internalise 
vesicles. This was achieved with murine macrophages utilising two separate 
detection approaches, flow cytometry and immunofluorescent imaging. Using 
these techniques, the time period required for uptake of labelled human 
vesicles by mouse BMDMΦ in vitro was evaluated. Using a pan-macrophage 
marker, CD11b, this study demonstrated that positive macrophages were 
present at a similar concentration from 0 to 18 hours after ECV addition. This 
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suggests that labelled vesicles did not affect the overall number of 
macrophages in culture over the 18-hour time period. As the study required a 
period of serum starvation, it was expected that there would be a proportion of 
CD11b negative cells. This study established the optimal time period required 
for human vesicles to be taken up by the primary cultured mouse 
macrophages. The data suggest that 12 to 18 hours is the most appropriate 
experimental time period for vesicle uptake by murine macrophages in vitro. 
Due to this finding, 18 hours was used as the peak time for vesicle incubation 
with macrophages for the remainder of the study.  
 
Using immunocytochemistry imaging, vesicle uptake was confirmed using 
Qdot tracker labelled human vesicles isolated from healthy volunteers and 
from patients with active vasculitis (pre-treatment). From the images obtained, 
this study has illustrated that ECVs can be engulfed by the murine 
macrophages and concentrated intracellularly. There was a clear red signal in 
multiple macrophages from the labelled ECVs. The images obtained were 
limited due to the macrophage positioning. Further optimisation is required to 
gather more detailed images of vesicle uptake with cells in a monolayer. The 
available representative images showed clear signal intracellularly and 
localised near the nucleus.   
 
To fulfil the second aim for this chapter, ECV uptake was also successfully 
established in human primary macrophages in vitro. By using cells from both 
species, it allows for a greater overview of the cell diversity in culture. It has 
been established that there is a high degree of heterogeneity in both mouse 
and human macrophage lineage,175 therefore comparing the two cell types 
optimised the assay for further studies. Additionally, the time required for ECV 
uptake in human macrophages was determined. The results gathered 
demonstrate that ECVs are engulfed by the cells after 24 hours and there is a 
similar amount of labelled ECVs after 48 hours when assessed qualitatively. 
This is similar to the time course in murine cells. Successful uptake in varying 
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time frames could be further confirmed by flow cytometry analysis. This would 
allow for more quantitative results.  
 
For the third aim of this study, in addition to macrophage uptake of ECVs, a 
human proximal tubule line was co-cultured with healthy human ECVs. 
Through immunocytochemistry, this again demonstrated successful uptake of 
vesicles at both 24 and 48 hours. Further studies have been planned to assess 
the effects of ECVs on the proximal tubule cell line expression of injury markers 
to mirror the damage caused by AAV with renal involvement. It would also be 
of interest to compare the injury readouts to AAV patients without renal 
involvement to ascertain whether there was a key mediator which was 
causative for kidney damage. Previous studies have shown that HAVCR1, also 
known as kidney injury molecule 1 (KIM-1), is able to distinguish relapse and 
remission with renal vasculitis.176 KIM-1 is detectable in many human kidney 
diseases, specifically when proximal tubule damage is present177 and 
correlates inversely with renal function.178 In AAV, previous studies have 
suggested that KIM-1 can distinguish between active AAV with renal 
involvement and once the disease is in remission,176,177 and correlates 
inversely with renal function.178,177 
 
Macrophage activation by vesicles  
This study demonstrated that ECVs isolated from humans can be taken up by 
murine macrophages and subsequently alter their phenotype in vitro. These 
effects were measured by qPCR measurement of a panel of cytokines which 
are secreted by macrophages after either classical or alternative activation. Of 
the genes studied, Mrc1 had the most statistically significant expression 
change. The expression of Mrc1 was upregulated in macrophages treated with 
pre- and post-treatment vesicles in comparison to the healthy controls. This is 
traditionally considered a marker of alternative activation of macrophages, 
which are considered to have anti-inflammatory and tissue repair roles as well 
as subduing the recruitment of additional immune cells.  
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An interesting result is that there is not a detectable change in human 
macrophage cytokine expression once co-cultured with ECVs from healthy 
volunteers and AAV patients. A possible explanation for the lack of difference 
between the test groups is the macrophage source. In future studies, it would 
be valuable to characterise the healthy volunteer cohort donating PBMCs to 
determine the possible differences observed between individuals. There are 
many features that could interfere with the healthy macrophage baseline 
results, such as infection and lifestyle factors, on their macrophage phenotype 
and therefore their cytokine production.82 In addition to this, the age of the 
blood donor could potentially be of importance for macrophage phenotype. For 
the previous experiments, macrophages from female donors aged between 23 
and 25 were cultured. By using donors of equivalent age to the AAV patients, 
we could assess the need for compatibility between the cells and ECVs in the 
study. In European studies, the mean age for AAV diagnosis is 60 years old179 
with a peak prevalence between 65-74 years old.121 The therapeutic strategies 
used for the treatment of AAV may also be a caveat, As the treatment 
strategies are based on immunosuppression, this may have an effect on their 
immune cell response to ECVs. This is again a limitation of using healthy 
macrophages for this study.  
 
Another feasible explanation for this is that the cargo of the ECVs were not 
appropriate to cause a detectable effect on the cells. Possible reasons for this 
are that the vesicle concentration is not high enough. This is however unlikely 
as a phenotypic effect has been detected in the murine macrophages and 
would, therefore, be expected to be sufficient for human cells. Alternatively, 
the cargo shuttled in the macrophage is not mediating the inflammation. It 
would also be valuable to sequence the ECV content in the patient groups and 
measure expression differences in AAV plasma samples and in the ECV 
fraction to compare the transportation in circulation. To confirm this, future 
studies will require the addition of a positive control for inflammation to ensure 
that the cells are capable of eliciting an immune response and that the gene 
expression is detectable. Further studies could be conducted to confirm 
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inflammation in the immune cells by measuring cytokine protein expression 
from the cells. This would allow for further confirmation of whether the cells 
had been altered by the patient’s vesicles. 
 
Human proximal tubule cells 
RPTECs were used in this study as an overall measurement for the uptake of 
vesicles within the nephron. RPTECs are well characterised proximal tubule 
cells which are therefore downstream of the glomeruli where the most extreme 
damage is observed in AAV patients with glomerulonephritis. It has been 
established that RPTEC/TERT1 cells are capable of ECV uptake after 24 
hours. To follow on from this, cells were co-cultured with ECVs from healthy 
controls and AAV patients following the protocol detailed above. As well as the 
human samples, cisplatin was used a positive control for established tubular 
damage as it is a known nephrotoxic agent. This was used at two 
concentrations, as determined by a dose-response curve. After co-culturing, 
HAVCR1 expression was measured from the treated cells alongside HAVCR1 
protein release into the cell supernatant by ELISA.180 This demonstrated that 
gene expression and protein concentration of HAVCR1 was lower at the higher 
dose of cisplatin than the other tested cells. This was an unexpected result, 
therefore we explored whether this could be a consequence of apoptosis. With 
apoptosis, the number of cells would be reduced, therefore the protein and 
gene expression would decline.  
 
Gene expression was measured for CASP3 and CSF1. For both genes, 
expression was greatly increased at 100M cisplatin. This suggests that renal 
damage has occurred. CASP3 is a marker of cell apoptosis and CSF1 plays a 
crucial role in macrophage recruitment for damaged cells in the proximal 
tubule. Cisplatin is known to cause direct damage to renal proximal epithelial 
cells as demonstrated in RPTEC/TERT1 cells.181 This, therefore, 
demonstrates an extreme and targeted form of renal damage, yet the ECV 
cargo would provide less direct assault. To refine this study, it would be 
necessary to include alternative controls to provide a spectrum of renal cell 
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injury. Overall, the finding of this study suggests that ECVs from healthy 
volunteers and patients with active vasculitis do not carry a cargo that is 
capable of causing renal cell damage to the same extent as a nephrotoxic 





In this chapter, ECV signalling in acute vascular dysfunction was assessed in 
vitro with immune and renal cells. It was established that ECVs can be taken 
up by immune cells in a time-dependent manner and can be visualised 
intracellularly. There was an immune response in murine macrophages but 
and no response in human primary macrophages when co-cultured with ECVs 
from patients with active disease in comparison to the healthy control vesicles. 
Furthermore, the ECVs were successfully taken up by renal cells but did not 
cause measurable cell injury in human proximal tubule cells. This is an 
important finding as this would suggest that the immune and renal cell 










The studies presented in this thesis sought to investigate the potential of miRs 
as markers of human vascular dysfunction. The major findings of my PhD are 
as follows: that the concentration of miR-126 is reduced in patients with active 
acute vascular dysfunction and increases once in remission; that miR-126 is 
low in CKD and ESRD and the circulating concentration increases following 
haemodialysis; that small RNA sequencing did not identify further miRs as 
biomarkers of disease relapse in ANCA vasculitis; and that ECVs isolated from 
patients with active vascular dysfunction did not cause an inflammatory 
response or renal cell damage in vitro.   
 
miR-126 in AAV 
The studies in Chapter 3 demonstrated that miR-126 decreases as vascular 
function declines in patients with acute vascular dysfunction. In patients with 
active ANCA vasculitis, the concentration of miR-126 is low and increases after 
successful treatment. It was also shown that in the circulation, miR-126 does 
not increase to a level seen in healthy individuals even after treatment. This 
may be representative of their continuing vascular damage as a result of the 
disease. miR-126 correlated with a gold standard measurement used to 
assess vascular health and arterial stiffness, PWV. The results suggest that 
there is a potential biomarker role for miR-126 to detect active disease in 
ANCA vasculitis. miR-126 has previously been examined as a potential 
biomarker for atherosclerosis,92 diabetes96 and cancers.182, 183 In addition, 
studies have suggested a potential role for miR-126 as a therapeutic strategy 
in chronic myeloid leukaemia.184  
 
In patients with ANCA vasculitis, the relapse rate is variable across studies 
(21% - 89%) for patients within 5 years.185 It would be of great interest to 
develop my study further and examine the potential of miR-126 to predict 
patients that have disease relapses and return to active disease. It is currently 
very challenging to clinically predict the patients that this will occur in, therefore 
by using miR-126 to routinely monitor the disease, it could be possible to alter 
treatment strategies to limit further vascular and organ damage. In contrast, it 
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could also predict the patients that no longer require such high doses of 
treatment, which could reduce treatment side effects.186  
 
A limitation of the studies in chapter 3 and 4 is that the healthy controls that 
were included were not age-matched with the patient cohorts. As ANCA 
vasculitis is a disease that mainly affects individuals between 65 and 74 years 
old,187 it is challenging to recruit healthy volunteers in this age group who do 
not have any co-morbidities and are not taking regular medication. In addition, 
it was not possible to obtain the healthy volunteer’s clinical parameter data, 
including arterial stiffness, inflammation status and renal function. Having 
these data would allow for further analysis of correlations with miR-126 and 
develop the potential for miR-126 as a biomarker of health and acute vascular 
dysfunction.  
 
miR-126 in CKD 
The studies in Chapter 4 support the potential role of miR-126 in vascular 
dysfunction, specifically in chronic disease. This chapter focused on CKD and 
ESRD with dialysis treatment. With chronic vascular injury, in moderate CKD, 
the concentration of miR-126 is reduced in comparison to healthy volunteers. 
In ESRD patients undergoing HD, miR-126 is further reduced when compared 
to moderate CKD, and this concentration increased following a single session 
of HD. miR-126 correlates with clinical measurements of vascular health, such 
as arterial stiffness. As a biomarker, miR-126 could guide treatment plans for 
ESRD to optimise the amount of time required for HD to avoid unnecessary 
sessions or treatment. In addition, miR-126 could be used as a prognostic 
marker to track CKD patient’s disease progression to ESRD. 
 
Developing a biomarker for CKD progression is essential as it is well 
established that patients with CKD are at an increased risk of developing and 
dying from CVD. This link is not fully explained by traditional risk factors, such 
as hypertension and diabetes mellitus.188 As miR-126 is a potential biomarker 
of vascular health, it may be valuable to track pharmaceutical dosing and 
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optimisation of dialysis sessions. For drug dosing, miR-126 could be used to 
assess the patient’s improving vascular health, using drugs such as statins. 
Statin-based treatments have been shown to reduce CVD risk in CKD patients 
who do not require HD, therefore tracking this would be valuable to assess the 
patient’s risk of CVD.189 
 
Small RNA sequencing for biomarker discovery in AAV 
Chapter 5 presents the results of a study using small RNAseq analysis to 
determine whether there are miR biomarkers which can differentiate between 
active ANCA vasculitis and remission. This study showed that the patients did 
not have differences in their miRNome. Additionally, the heterogeneity of the 
condition was confirmed. Due to the reduction in patient samples that were 
included in the RNAseq analysis, because of abnormal boxplot distributions, 
the study was underpowered. As the number of paired samples were reduced 
from 15 to 10, this consequently reduced the proportion of genes with ≥ 80% 
power from approximately 50 to 40 with the loss of these paired samples. This 
was a major limitation for this study. It would be beneficial to repeat this study 
with a larger sample size, and if possible, include patients that had active 
disease relapse. 
 
ECVs as markers and mediators of AAV 
In Chapter 6, the studies examined whether ECVs isolated from patients with 
active ANCA vasculitis contained a pathognomonic cargo which would cause 
inflammatory and renal damage. ECVs were taken up by immune cells over 
18 hours and imaged intracellularly in murine and human-derived 
macrophages. There was not a defined immune response in the immune cells. 
An additional study examined ECV uptake in renal epithelial proximal tubule 
cells in vitro. Uptake was observed by fluorescent microscopy, however, there 
was no renal cell damage identified qualitatively. Together, this suggests that 
the immune and renal cell response is initiated by alternative factors which are 
not directly mediated by ECV uptake. 
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A limitation of this study was that the phenotypic changes in immune cells were 
not shown in control samples. To do this, macrophages would be stimulated 
with exogenous LPS/IFNγ to elicit a classical phenotype (M1) and IL4/IL13 for 
an alternative phenotype (M2). The gene expression for the cells could then 
be compared from macrophage and ECVs alone versus cells that are pre- 
stimulated. This would confirm that the macrophages could be successfully 
stimulated to elicit a switch of macrophage phenotype and compare this to 
switching mediated by ECVs during active vascular dysfunction. 
 
Future work 
From the results obtained in the studies presented in this thesis, further 
questions have been raised and additional areas identified to examine. Details 
of a selection of these are discussed below. 
 
1. miR-126 as a therapeutic target in AAV 
Building on the results obtained in Chapter 3, it would be of interest to 
determine if miR-126 is a mediator of ANCA vasculitis and translates the 
human data into a mouse model. As miR-126 is a key vascular regulator, it is 
proposed that it is a mediator and potential treatment for vasculitis. This study 
would determine the effect of miR-126 treatment in a mouse model of 
vasculitis.  
 
To do this, the study could examine the effect of systemic delivery and 
antagonism of miR-126 in nephrotoxic nephritis mouse (NTN), a widely 
accepted and reproducible model of human rapidly progressive 
glomerulonephritis that reflects the histological changes observed in ANCA 
vasculitis.190 Nephrotoxic nephritis would be induced in C57/BL6 male mice at 
10-12 weeks of age. NTN can be initiated in mice by intravenous injection of 
sheep anti-glomerular basement membrane nephrotoxic serum as previously 
described.190 For in vivo treatment, mice would be randomised and 
administered miR-126 mimic or antagomiR-126.  Mice would be administered 
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miR and antagomiR in a preventative (pre-NTN) and therapeutic (post-NTN) 
manner. For a preventative strategy, antagomiR treatment would be delivered 
by IV injection 3 days before the initial NTS injection.  
 
As a readout of the treatment, tissue sampling could be conducted, including 
blood, urine and histology. The drug delivery would be confirmed in the blood, 
kidney and the vasculature by direct measurement of miR, using qRT-PCR for 
gene expression and in-situ hybridisation. Vascular function would be 
assessed by wire myography of aortic and mesenteric vessels191 and kidney 
injury by histology and assessment of proteinuria as described.192 These 
studies would define the role of miR-126 in the vascular and renal dysfunction 
seen in NTN. 
 
2. miR-126 in transplantation 
Following the measurement of miR-126 in dialysis patients, a future study that 
would be beneficial would be examining miR-126 in renal transplant patients. 
This would directly compare the circulating concentration of miR-126 in 
patients with ESRD and their potentially improved vascular and renal function 
following a kidney transplant. Previous studies have shown conflicting 
evidence for the changes in overall vascular health and arterial stiffness in 
patients with renal transplants.193 By measuring miR-126 is the transplant 
patient’s blood, it could potentially be used to monitor the changes in vascular 
integrity from CKD to ESRD with HD to recovery following transplantation.  
 
3. Small RNAseq in patients with vascular dysfunction 
To improve and adapt the RNAseq study described in this thesis, it would be 
beneficial to increase the ANCA vasculitis cohorts pre- and post-treatment to 
add power to the study. To further assess the miRNome differences in patients 
with vascular dysfunction, it would be advantageous to expand the study to 
include both acute and chronic vascular damage. This would include the 
patients described in this thesis with managed and moderate CKD, ESRD with 
maintenance dialysis and also healthy individuals. In doing this, a direct 
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comparison of each phenotype of vascular dysfunction could be compared and 
further biomarkers identified for diagnostic and prognostic uses.  
 
Final conclusion 
Through a series of in vitro, ex vivo and clinical studies, this thesis has explored 
and shed light on miRs as potential biomarkers of acute and chronic vascular 
dysfunction. MiR-126 is a promising marker for acute and chronic vascular 
dysfunction, as demonstrated in patients with ANCA vasculitis, CKD and 
ESRD. RNAseq did not determine alternative miRs to compliment miR-126 is 
ANCA vasculitis. Additionally, the transfer of ex vivo ECVs from patients with 
active vascular dysfunction did not affect murine and human-derived 
macrophages or immortalised renal proximal tubule cells. Further experiments 
are required to fully understand the diagnostic and prognostic value of miR-
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